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Early cancer diagnoses promise to improve treatment outcomes and patient
survival rates. However, current cancer diagnostics often rely on finding a tumor,
making early detection difficult and possibly compromising therapy outcomes.
Screening for cancer without tumor detection can be based on assays of body
fluids such as serum or plasma for cancer biomarker proteins to provide an
instantaneous record of a patient’s disease status. Measurement of these
biomarker proteins should be accurate, sensitive, cheap and preferably at pointof-care (POC) for translation to the clinic. In addition, due to low predictive power
of some biomarker proteins and their over-expression by multiple cancer types, it
is essential to measure panels of biomarker proteins as opposed to a single
biomarker for reliable diagnosis of cancer. Simultaneous measurement of the
levels of a panel of biomarker proteins can lead to more accurate diagnoses and
offer clarity about disease characteristics and progression that may help guide
treatment strategies.
The long-term goal of this thesis research is to provide multiple biomarkerbased diagnostics to enable accurate early detection of cancer and therapy
i

monitoring. A simple, low-cost, 8-electrode semi-automated modular microfluidic
system for on-line capture and electrochemical detection of panels of cancer
protein biomarkers was designed and validated. Proteins that were validated
include oral cancer biomarkers (IL-6 & IL-8) and oral mucositis biomarkers (IL-6,
TNF-α, IL-1β and CRP). This thesis also describes our first electrochemical
assay for parathyroid hormone related peptide (PTHrP); a paraneoplastic peptide
responsible for hypercalcemia in cancer patients and also implicated in cancer
metastasis. Also described in the dissertation, is a novel 16-electrode
electrochemical set up for simultaneous detection of upto 8-prostate cancer
biomarkers, many of which are thought to be specific for aggressive prostate
cancer. Measurement of these small panels of selective biomarkers holds
remarkable promise for future cancer diagnostics and personalized cancer
therapies and most importantly in identifying aggressive vs indolent forms of
prostate cancer.
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CHAPTER ONE
Introduction
1.1 Goal and Significance
Despite tremendous efforts to develop strategies against cancer-related
mortality, cancer still remains a major public health problem in the United States
and throughout the world. It is the second leading cause of death in the United
States after heart disease.1 Cancer arises in 1 out of 3 individuals and affect
people of all ages and certain types of cancer arises more according to the
gender, age or geo-graphical location globally.2 According to the National Cancer
Institute one out of every four deaths occurring daily in the US is due to cancer.
In 2016 alone, 1,685,210 new cancer cases are projected to occur in the US
which translates to 4,600 new cancer diagnoses each day.1 The lifetime
probability of being diagnosed with an invasive cancer is 42% in men and 38% in
women. It is also estimated that 595,690 Americans are expected to die in 2016,
corresponding to about 1,600 deaths per day.1 These deaths arise mostly from
cancers of the lung and bronchus, prostate, breast and colorectal cancer which
accounts for 46% of all cancer deaths.1
Cancer is a multi-gene, multi-step disease originating from a single
abnormal cell of clonal origin with an altered DNA sequence (mutation).3
Uncontrolled proliferation of these abnormal cells leads to successive rounds of
mutation and natural selection resulting in formation of tumors (Figure 1.1).

1

Subsequent mutation leads to malignant tumor which breaks through the basal
membrane and spread to distant locations.3-5

Figure 1.1: Clonal expansion of mutation leading to formation of tumors
(Adapted from reference 3).

Initiation and progression of cancer depends on both external factors/
environmental factors (diet, lifestyle and exposure to ultraviolet radiation or
carcinogenic pollutants) and internal factors within the cells (inherited mutations,
hormones, immune conditions, and mutations that occur from metabolism). 1,3
These factors act together or in sequence, resulting in abnormal cell behavior
and excessive proliferation. As the causes of cancer are so diverse, there are
many types of cancer. There are more than 200 types and sub-types of cancer
affecting more than 60 human organs.4 The dysregulation in normal signaling
pathway in cancer patients leads to inactivation of tumor suppressor genes and
2

activation of oncogenes.6 However, in terms of diagnosis, no single gene is
universally altered during this process, and the patterns of change differ in
tumors from different organs, as well within tumors from the same location. In
addition, approximately 90% of all cancer-related deaths occur from metastasis
and not directly from the primary tumor site.7 Therefore, there is urgent need to
develop tools for early diagnosis of cancer to improve treatment outcomes and
patients’ survival rate.
Existing methods of screening for cancer often rely heavily on finding and
imaging a tumor. Imaging modalities such as magnetic resonance imaging (MRI),
positron emission tomography (PET), and computed tomography (CT), use
contrast materials to distinguish between different anatomical features of tumor. 2,
8-10

These techniques determine the precise location of tumor thereby aiding in

directing treatment options, monitoring cancer therapy and recurrence of the
disease. Unfortunately, some tumors fail to show a marked difference from
surrounding healthy tissue due to uptake of the contrast agent. In addition, some
of the techniques lack the sensitivity to detect small (<1 cm) and low grade
tumors leading to false negative results. Furthermore, most of these techniques
are also expensive and hence might not be available or affordable in low
resource settings.11-13 Other techniques employed for screening of cancer rely on
traditional methods based on cell morphology using staining and microscopy.6
These are invasive techniques based on taking a biopsy and then examining the
tissue using cell fixation and morphology approaches to identify and detect
3

cancer cells. These tests, however, are not individually conclusive as tissue
removal can miss cancer cells at the earlier onset of the disease and further
research is needed to develop tests to identify the malignancy without the need
for invasive examinations.6
The goal of this dissertation was to develop and validate a simple, lowcost technique that allows patients to be screened for cancer without undergoing
any invasive procedure. The methodology is based on assaying bodily fluids
such as serum or plasma to measure the levels of biomolecules that are over- or
under-expressed during early cancer stages.14,15 These biomolecules also known
as cancer biomarkers can deliver a “snapshot” of disease status in patients. The
technique addressed in this thesis for detection of these cancer biomarkers,
employs different aspects of automation, microfluidics, nanotechnology and novel
labeling methods in conjunction with electrochemical detection. First, the semiautomated microfluidic device was first optimized and validated with experimental
samples consisting of conditioned media from human oral cancer cells, followed
by real-time monitoring of small biomarker proteins panel for oral cancer and
prostate cancer in human serum and plasma. The clinical data obtained from the
semi-automated device along with the low cost of the assay holds excellent
promise for cancer diagnosis and therapy monitoring.

4

1.2 Cancer Biomarkers
According to National Health Institute (NIH), a biomarker is defined as “a
characteristic that is objectively measured and evaluated as an indicator of
normal biologic processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention.”16 According to the definition, a cancer biomarker is
a biological molecule found in blood, other body fluids or tissues that is indicative
of the presence of cancer in body. It might be a molecule secreted by a
malignancy itself, or it can be a specific response of the body to presence of
cancer. Cancer biomarkers typically differentiate an affected patient from a
person without a disease. The alterations could be due to a number of factors,
including germline or somatic mutations, transcriptional changes and post
translational modifications.
There

is

tremendous

variety

of

biomarkers,

including

DNA,

DNA

modifications, RNA, proteins, hormones and related molecules, molecules of the
immune

system,

oncogenes

and

other modified

molecules. 6,17

Cancer

biomarkers can also be a collection of alterations, such as gene expression,
proteomic and metabolomics signatures. Biomarkers can be detected in
circulation (whole blood, serum or plasma), or excretions or secretions (stool,
urine, sputum or nipple, discharge) and thus easily assessed non-invasively, or
can be tissue driven and require either biopsy or special imaging for evaluation.
Genetic biomarkers can be inherited and detected as sequence variations in

5

germ line DNA isolated from whole blood, sputum, or buccal cells or can be
somatic and identified as mutations in DNA derived from tumor tissue.18
Cancer biomarkers have many potential applications in oncology,
including risk assessment, screening, differential diagnosis, determination of
prognosis, prediction of response to treatment, and monitoring status of the
disease, either to detect recurrence or determine response or progression to
therapy. In addition, biomarkers can be used in combination with imaging
techniques to detect cancer in vivo and assess response to therapy.17 Because
of the critical role that biomarkers play at all stages of disease, it is important that
they undergo rigorous evaluation, including analytical validation, clinical
validation, and assessment of clinical utility, prior to incorporation into routine
clinical care.18

1.2.1 Cancer Protein Biomarkers
One most important class of cancer biomarkers include proteins that are
elevated or depressed in serum or plasma patients and their levels indicate the
presence of cancer in the body.19 These proteins are often specific to one or
several types of cancer and the levels of such proteins can give clear indication
of the patient’s status.20 Cancer biomarker proteins have been identified for
almost every major type of cancer, however only a few of the biomarkers have
been approved by FDA (Table 1.1).
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Table 1.1: List of FDA approved protein markers currently used in clinical
practice
Protein
Biomarkers
Cancer antigen125 (CA-125) +
Human
epididymis
protein 4 (HE4)
HE4
AlphaFetoprotein
(AFP)

CA19-9
CA15-3

CA27.29
Free PSA
Thyroglobulin
(Tg)
Total PSA
Carcinogenic
embryonic
antigen (CEA)

Clinical use

Cancer

Specimen

Year
Approved
2011

Prediction of malignancy,
monitoring disease
progression, response to
therapy

Ovarian
cancer

Serum,
Plasma

Monitoring recurrence or
progression of disease
Staging of nonseminomatous testicular
cancer
Risk assessment for
development of disease
Monitoring disease status

Ovarian

Serum

2008

Hepatocellular
Testicular

Serum,
plasma,
amniotic
fluid

2005

Pancreatic

2002

Monitoring of disease
response to
therapy/assessment of
therapy
Monitoring disease
response to therapy
Discriminating cancer from
benign disease
Aid in monitoring

Breast cancer

Serum,
Plasma
Serum,
Plasma

Breast cancer

Serum

1997

Prostate
cancer
Thyroid

Serum

1997

Serum,

1997

Screening & monitoring
disease
Aid in management and
prognosis

Prostate

Serum

1986

Pancreatic
cancer

Serum,
Plasma

1985

1997

Many of these proteins are secreted into the blood at higher than normal
levels when cancers begin to develop and are useful for diagnosis even before
the onset of tumours.14 For example prostate specific antigen (PSA) is a serum
protein biomarker recommended by the American cancer society as an early
screening tool for prostate cancer. PSA is produced by the cells of the prostate
7

gland and is typically elevated in the presence of prostate cancer. A PSA serum
concentration of 4−10 ng mL−1 suggests the possibility of early stage prostate
cancer, while normal levels are typically 0.5−2 ng mL −1 and late stage prostate
cancer is characterized by values above 100 ng mL -1.14,19 Interleukin-6 (IL-6) on
the other hand is a multifunctional cytokine associated with several different
cancers, including head and neck squamous cell carcinoma (HNSCC). Mean
serum IL-6 levels in healthy individuals are typically less than 6 pg mL −1, whereas
in patients with HNSCC, the levels are 20 pg mL−1 or greater. Serum IL-6 is also
elevated in colorectal, gastrointestinal, and prostate cancers. 21 Protein
biomarkers are also used to monitor response to therapy and recurrence of
disease in ovarian, pancreatic and colon cancer, through measuring the proteins
cancer antigen (CA125), CA19-9 and carcinoembryonic antigen (CEA),
respectively.17
However, single biomarker proteins typically have insufficient positive
predictive value e.g about 70% for PSA which is one of the better single
biomarkers.22 PSA has low specificity to prostate cancer as the levels can also
be elevated above the threshold in benign prostate hyperplasia (BPH), a
condition in which the prostate enlarges, prostatitis (prostate inflammation) and
urinary infection. In addition, PSA fails to discriminate between aggressive
tumors from low-risk ones and between malignant disease and other benign
prostate conditions, and as such, over-diagnosis and over-treatment represent
critical consequences of PSA-based screening. Failure to distinguish between
8

indolent and more aggressive forms of cancer is also a common problem with
other clinically used single biomarkers, including CA 125 for ovarian cancer, CA
19-9 for pancreatic cancer and CEA for colon cancer.20 Owing to low inherent
predictive ability of some biomarkers and their overexpression by multiple cancer
types, highly reliable prediction for a specific cancer ultimately require measuring
a number of relevant biomarker proteins for each cancer. Multiple protein
measurements have been shown to improve both the specificity and sensitivity of
the diagnostic tests.15,20
For example, detecting 5 or more biomarkers for a given cancer by liquid
chromatography-mass spectrometry (LC-MS) has provided >99% reliable
diagnostics.6,23

Lumachi

and

his

co-workers

used

simple

multianalyte

immunoassay for measurement of five protein biomarkers CEA, CA 19-9 and 724, cytokeratin-19 fragment (CYFRA 21-1), and osteopontin, comparing their
expressions in patients with colorectal cancer and age- and sex-matched
patients suffering from confirmed benign colorectal diseases (controls). Single
marker measurements showed low specificity and sensitivity; however,
simultaneous measurements of all five markers achieved 74.1% sensitivity and
94.3% specificity in patients with colorectal cancer.24 Karl and colleagues
evaluated expression of known markers hemoglobin (iFOBT), hemoglobinhaptoglobin, calprotectin, carcinoembryogenic antigen, and the novel fecal
markers tissue inhibitor of metalloproteinase-1 (TIMP-1) and S100A12. The
combination of S100A12, immune-FOBT, and TIMP-1 reached sensitivity greater
9

than 80% at a high specificity (98%), giving a novel noninvasive colorectal cancer
screening tool.25 Also, when human Kallikrein 6 (hK6) is combined with CA-125,
at 90% specificity, sensitivity increases to 72% (for all patients) and to 42% in
stage I or II of ovarian cancer.26 The diagnostic sensitivity of serum hK6 alone at
90% and 95% specificity is 52% and 47%, respectively, in the whole patient
population (n=238). For early stage disease (stage I or II), sensitivity is
approximately 21% to 26%. However, measurements of the multiple biomarker
proteins need to be done at high accuracy and cheaply at point-of-care, e.g. in a
physician’s office or clinic, to reduce costs, minimize sample decomposition,
facilitate-on the-spot diagnosis, and alleviate patient stress.15
1.3 Platforms for Cancer Biomarker Detection
1.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
Currently, most clinical protein biomarker detection is done using an
enzyme-linked immunosorbent assay (ELISA). Since its introduction in 1971,
ELISA has remained the gold standard method for protein measurements. 27 In
ELISA, primary antibodies are attached onto a 96-well plate to selectively capture
the analyte protein from the sample. After washing, a secondary antibody with a
label attached is added, and binds selectively to the protein on the surface. A
substrate that reacts with enzyme label is then added to produce a colored
complex detected optically (Scheme 1.1). Success of ELISA stems from enzymebased amplification mode and ease of use, along with the specificity and
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sensitivity of antibody-antigen interactions common to all immunoassays.28
ELISA-type approaches have been quite useful in assays utilizing immunoarrays.
However, with the demand for multiplexing capability, shorter analysis time,
smaller sample volume and higher sensitivity, other techniques are being
explored for protein determinations.29,30

Scheme 1.1: ELISA Scheme; Antigen is added to ELISA plate coated with
primary antibody, followed by addition of secondary antibody conjugate by
enzyme label. Generation of signal is by addition of a substrate that forms a
colored product that can be measured by an optical plate reader.

1.3.2 LC-MS based Proteomics & Commercial Assays
Liquid chromatography coupled with mass spectrometry (LC-MS)-based
proteomics

can

achieve

multiple

biomarker

measurements

approaching

acceptable sensitivity. However, the current analysis technology is too
expensive, time consuming and technically complex for routine clinical
diagnostics.17,31 At present, LC-MS-based proteomics is more suited for
biomarker discovery research. Alternatively, analyzers based on antibody-coated
11

microarrays are being developed in 96- or 384-well plate format (Quansys
Biosciences, SA Biosciences). Analyte proteins are captured by primary antibody
or aptamers on each spot on the array and after washing with buffer designed to
minimize non-specific binding, a labeled secondary antibody dispersion is added
to bind to the analyte proteins. A substrate is then added to react with enzyme
label to generate optical or electrical signal. These arrays are highly selective
and sensitive, easy to use, less costly and have multiplexing capabilities.
Currently, there are several commercially available automated and semiautomated analyzers for multiplexed protein measurements of upto 10 selected
target proteins per sample with detection limits ranging from 1-100 pg mL-1 in
serum.15 These analyzers are based on surface plasmon resonance (Horiba Inc,
BIO-RAD), fluorescence (Luminex, Myriad RBM), electrochemiluminiscence
(Roche

Diagnostics,

Mesoscale

Discovery)

measurement

technologies.

However, these commercial instruments are not suitable for point of care
applications in resource limited settings as they require specialized consumables
including sample well plates, chips, and reagent kits which are very costly.
Fluorescence-based detection strategies on the other hand require laser sources
and precise alignment of optical components.19 Therefore, there is still a need for
a simple, low-cost device for multiple protein measurements that could be
employed in resource limited settings.
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1.3.3 Electrochemical Methods
Electrochemical methods have recently attracted considerable interest
because of their sensitivity, low cost and inherent minitiarization. In 1980s,
Heineman and Halsall pioneered enzyme-linked electrochemical immunoassays
for small molecules and proteins.32 In their approach, antibody-antigen binding
events and enzyme substrate reactions were separated in space and time from
detection of electroactive products. Electroactive products formed from the
enzyme label alkaline phosphatase are transported by a chromatographic or
fluidic system to the detecting electrode. Advances have included interdigitated
electrodes to achieve high sensitivity and incorporation into microfluidic devices.
Excellent detection limits in the pg mL-1 to ng mL-1 range have been obtained for
proteins and small molecules depending on the design and nature of the
electrochemical detector.33-35
Since the introduction of enzyme-linked electrochemical immunoassays by
Heineman, various electrochemical methods such as voltammetry (linear sweep,
differential pulse, square wave) and amperometry have been widely applied for
sensitive detection of cancer protein biomarkers.19 These methods employ a
detection antibody (Ab2) labeled with an electroactive species that is allowed to
bind with the analyte (Figure 1.2). The analyte bound on the labeled-Ab2 is then
introduced onto primary antibody (Ab1)-modified electrode surface to complete
the sandwich assay. The concentration of the targeted protein biomarker is
quantified by applying a potential and measuring the resulting current at the
13

electrode. The applied potential drives the redox reaction of the labeled
electroactive species and provides a current signal that is proportional to the
concentration of the protein analyte.19,33

Figure 1.2: Illustration of electrochemical method for protein biomarker detection.
Signal generated is proportional to the concentration of the target analyte. Labels
commonly employed include horseradish peroxidase (HRP) and alkaline
phosphatase.

In order to increase the sensitivity of the electrochemical immunoassays,
nanomaterials such as gold nanoparticles, carbon nanotubes (CNTs), magnetic
beads and quantum dots have been incorporated into the assays as substrates
for the capture antibodies or for target antigens. 14,15,19,33 Signal amplification for
target protein detection can be achieved by loading greater numbers of
biomolecules or multi-enzymes onto nanomaterials. These approaches greatly
14

enhance sensitivity by providing a large number of labels for each protein bound
on the sensor surface. Nanostructured sensor surfaces can also provide
additional increases in sensitivity by providing high surface areas enabling
attachment of a large number of capture antibodies, and by facilitating better
access of protein analytes to these antibodies.19,33
Our laboratory has employed enzyme-coated magnetic beads along with
sensors nanostructured with gold nanoparticles and CNTs to achieve high
sensitivity. Gold nanoparticle immunosensor was fabricated by depositing a
dense 5 nm layer of glutathione-decorated gold nanoparticles onto a 0.5 nm
polycation layer, on a pyrolytic graphite.36 Detection limit of 0.5 pg mL-1 was
achieved using 1 μm magnetic bead-Ab2-horseradish peroxidase (HRP)
bioconjugates, coated with 7500 HRPs per bead. Good correlation was found
between the immunosensor level of PSA in patient samples with the standard
ELISA. Immunosensor responses were measured by rotating disk amperometry,
using H2O2 to activate HRP to ferryloxyHRP species and hydroquinone as an
electron mediator, which resulted in a steady state current proportional to protein
concentration (Scheme 1.2).
Immunosensor for PSA in serum using multi-labeled CNT-HRP-Ab2
particles using this approach gave detection limits of 4 pg mL-1.37 SWCNT
immunosensors were also used to measure PSA levels in 1000 prostate cancer
cells laser dissected from prostate tissue. These immunosensors achieved a
detection limit of 0.5 pg mL−1 for IL-6 released from a variety of oral cancer cells
15

into cell growth media.38 SWCNT forests provided 5 to 10-fold better sensitivity
than immunosensors without nanotubes because of a large increase in density of
Ab1 compared to that on a flat immunosensor.33

Scheme 1.2: Generation of signal from HRP. H2O2 activates HRP to
ferryloxyHRP (1) form which further oxidizes hydroquinone to benzoquinone (2).
Signal is generated via a two electron transfer reaction regenerating
hydroquinone (3).

We recently employed AuNPs immunosensors for amperometric detection
of PSA and IL-6 with magnetic bead conjugates labeled with 90,000 Ab 2 and
~200,000 HRPs. With this method, PSA and IL-6 were analysed down to 0.1 pg
mL-1 and 0.25 pg mL-1 respectively, in 5000-fold diluted calf serum.39 Increasing
the number of labels on the magnetic bead surfaces to 400,000 HRPs, increase
the sensitivity of the assay further (Figure 1.3). Limits of detection of 10 fg mL-1,
16

15 fg mL-1, 8 fg mL-1, and 60 fg mL-1 were reached for IL-6, IL-8, vascular
endothelial growth factor (VEGF) and VEGF-C respectively in 5000-fold diluted
calf serum.40 In collaboration with Munge et al, an unprecedented DL of 1.0 fg
mL−1 for IL-8 using magnetic bead bioconjugates with a half-million HRP units
each was achieved. An added advantage is that tens of thousands of antibodies
can be included on 1 μm beads, promoting binding of analyte proteins to the
beads at concentrations well below what can be achieved with a single
antibody.41

Figure 1.3: AuNPs Immunosensor for amperometric detection of cancer protein
biomarkers using magnetic bead conjugates labeled with thousands of Ab 2 and
HRPs.

17

1.4 Microfluidics for Biomarker Detection
Since its introduction in 199042, microfluidics also known as lab-on-chip
(LOB) or micro total analysis (mTAS), has attracted a lot of interest and grown
explosively. Microfluidic technology possesses remarkable features for simple,
low-cost and rapid disease diagnosis, such as; (1) increased surface-to-volume
ratio for efficient mass transport in immunoreactions leading to fast analysis; (2) a
miniaturized

microchannel

dimension

to

reduce

sample

and

reagent

consumption; (3) high portability along with automated integration with other
functions such as valves, pumps, mixtures and detectors; and (4) analysis of
complex biological fluids with high sensitivity for health care applications. 43,44 An
enormous number of microfluidic devices have been developed for biomedical
applications. These devices enable on-chip POC diagnosis and real-time
monitoring of diseases from a small volume of body fluids. These microfluidic
devices may act as a bridge to improve the global health care system with high
efficiency and sensitivity, especially for remote areas with low-resource settings,
such as the underdeveloped and developing countries, in home health care
setting, and in emergency situations. Because of all these significant features,
numerous microfluidic devices have been developed for biomarker detection in
cancer diagnosis.43
Microfluidic chips for immunoassays are commonly fabricated from silicon,
glass, and polymer materials.44 The first generation of microfluidic devices were
made from silicon and glass by photolithography and wet-etching. However,
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polymers such as polymethylmethacrylate (PMMA), cyclic olefin copolymer,
polystyrene, and polydimethylsiloxane (PDMS) and paper-based microfluidic
devices have emerged as alternative materials to silicon and glass due to the
simple fabrication process (e.g., molding, printing) and low cost. 45-47 Among the
polymers,

PDMS

is

the

most

popular

material

used

for

microfluidic

immunoassays because of its flexibility, optical transparency, biocompatibility
and low-autofluorescence properties. Furthermore, PDMS can be easily bonded
to silicon, glass or another piece of PDMS through treatment with oxygen
plasma.43,44
In recent years, great efforts have been devoted for the development of
electrochemical detection-based microfluidic devices for detection of cancer
biomarkers. For example, Li et al. developed an electrochemical ELISA on
paper-based microfluidic devices.48 Paper-based microfluidic devices were
fabricated by patterning chromatography paper using the photolithography
technique. Working and counter electrodes were screen printed from graphite
ink, and a reference electrode from silver/silver chloride ink. The electrochemical
ELISA of IgG based on cyclic voltammetry (CV) was demonstrated with the LOD
of 3.9 fM. Liu et al. developed a PMMA microfluidic chip coupled with a threeelectrode electrochemical detection system to detect the trace level of AFP. 49 For
covalent immobilization of the AFP monoclonal antibody, PMMA microchannels
were first modified with poly(ethyleneimine). The captured analyte, AFP, was
finally bound to the HRP-conjugated AFP antibody for electrochemical detection.
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When the substrate mixture of 2-amino hydroxybenzene and hydrogen peroxide
was pumped into the PMMA microchannel, the HRP enzyme labeled on the AFP
antibody within microchannels instantaneously catalyzed the substrate, and the
generated electroactive 3-amino phenoxazine was detected using DPV. The
immunochip had the LOD of 1 pg mL−1 for AFP with a detectable linear
concentration range of 1–500 pg mL−1.

Figure 1.4: (A) Electrochemical microfluidic set up for off-line detection of cancer
protein biomarkers. (B) Detection chamber housing the Ab1-modified 8-electrode
array.

Our first microfluidic electrochemical immunoassay for multiplexed
detection of cancer biomarkers was made up of a molded PDMS channel
sandwiched between two PMMA plate and interfaced with a pump and sample
20

injector (Figure 1.4). The detection chamber was 63 μL volume in size and easily
housed the 8-electrode array. Prior to incorporation of the array onto the
detection chamber, the array was coated sequentially with a layer of PDDA,
AuNPs and Ab1 as described in Figure 1.3. Protein analyte were captured off-line
by magnetic bead conjugate and then introduced into the detection chamber to
be captured by the primary antibody on the surface of the array. Detection of the
target analyte was performed amperometrically by injecting a mixture of
hydroquinone and hydrogen peroxide. This microfluidic device was employed for
detection of oral cancer and prostate cancer biomarkers.38,39 For POC
applications, the assays needs to be automated such that it only requires loading
of reagents and samples.

1.5 On-line Protein Analyte Capture
Point-of-care devices require simple, low cost, adequately sensitive and
technically undemanding automated methodology for personalized cancer
diagnostics and therapy.14,15,19 However, most immunoassay techniques employ
manual off-line protein analyte capture. Protein analytes are captured from serum
by magnetic bioconjugates in small vials, outside microfluidic device, prior to
being introduced to the Ab1-modified array (Figure 1.3). In addition, most
immunoassay steps are performed manually limiting their applications for POC
applications.
This thesis addresses for the first time, development and validation of a
simple, low-cost, semi-automated microfluidic device for cancer biomarker
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protein detection.50 The microfluidic immunoassay system incorporates an online protein capture chamber into the previously reported modular device by
Chikkaveeraiah et al. (Figure 1.4).39 This chamber feature layer of molded,
flexible PDMS sandwiched in between two flat, machined PMMA plates. The
assembly is bolted together tightly to form an oval cylinder channel 1.5 mm wide
and 100 ± 2 μL in volume housing a tiny magnetic stir bar (Figure 1.5). Flow out
of the channel is directed to waste or to the detection chamber by a switch valve.
Protein analytes are captured from biomedical samples by magnetic bead
conjugates in the on-line capture chamber. The protein-magnetic bead conjugate
is then magnetically separated, washed and introduced into the detection
chamber housing an 8-electrode screen printed carbon arrays coated with
glutathione protected gold nanoparticles (GSH-AuNPs).
Inclusion of the on-line protein capture module provides a more automated
strategy compared to the earlier device that required off-line capture since
capture and washing are done in the microfluidic system, not manually as
previously (Figure 1.4). In addition, most immunoassay steps are incorporated
into the microfluidic device, requiring only loading of reagents, samples and wash
solutions by the operator. The assay requires relatively short time of 30 min,
which is less than 50 min for the off-line capture assay and much less than
standard ELISA (>2 hrs) and other commercial detection methods. Thus, assay
time and level of automation begin to approach the needs of POC applications.
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Figure 1.5: (A) Conceptual instrumentation and strategy for ultrasensitive
amperometric detection by microfluidic immunoarray and (B) photograph of
capture chamber in which target proteins will be captured on-line from the
sample by heavily labeled HRP-antibody-magnetic beads to form protein-bead
bioconjugates.

1.6 Summary/Overview of dissertation
In this Ph.D. research thesis, the main goal was to develop a low-cost
semi-automated point-of-care diagnostic devices that can be used for rapid and
sensitive measurement of protein biomarkers for various types of cancer. The
immunoassay devices should ideally be affordable to use in any biomedical
laboratory for mass screening of patient population especially in resource limited
settings. This thesis is composed of 5 chapters.
Chapter 1 provides introduction to protein cancer biomarkers and various
platforms employed for detection of the cancer protein biomarkers. This chapter
also highlights electrochemical based protein detection strategies that are
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currently implemented in the sensitive detection of biomolecules & biomarker
proteins and also the importance of integration of microfluidics into immunoassay
devices. The chapter also includes a summary of the goals of various projects in
the thesis and the research background which served as a concrete foundation
to the work presented in this thesis.
Chapter 2 describes a novel simple, low-cost semi-automated modular
microfluidic device for on-line capture and detection of oral cancer protein
biomarkers and oral mucositis biomarkers. This system incorporates an on-line
capture chamber where protein analytes are captured from biomedical samples
by magnetic bead conjugates. Ultralow detection limits of 5 fg mL -1 and 10 fg mL1

were achieved for simultaneous detection of two oral cancer biomarkers and

four oral mucositis biomarkers respectively. Accuracy and diagnostic utility of
these microfluidic arrays were demonstrated by measuring the levels of the oral
cancer biomarkers in conditioned media of oral cancer cell lines. The levels of
oral mucositis biomarkers were also measured in serum of head and neck cancer
patients undergoing radiotherapy and compared with standard ELISA to
demonstrate the accuracy of the immunoarray. The use of microfluidic
immunosensors to measure concentrations of elevated biomarkers holds
promise for accurate, low cost, and rapid determination of oral cancer and also
determination of projected risk of oral mucositis that can be used by dentists and
oncologists for patient management.
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Chapter 3 describes the first application of the on-line modular microfluidic
device for detection of a peptide, parathyroid hormone-related peptide (PTHrP).
PTHrP is recognized as the major a causative agent of humoral hypercalcemia of
malignancy (HHM) and it has also been implicated in tumor progression and
metastasis of many human cancers. The first ultrasensitive multiplexed assay to
measure intact PTHrP 1-173 as well as circulating N-terminal and C-terminal
peptide fragments is described in this chapter. Using, ink-jet printed gold
nanoparticles immunoarray, limits of detection (LOD) of 3 fg/mL (~1000 fold
lower than IRMA) were achieved for simultaneous detection of PTHrP isoforms
and fragments in 30 min. Good correlation for patient samples was found with
immunoradiometric assay (IRMA) (n=57); r2=0.99 assaying PTHrP 1-173 and 186 fragment. Analysis by ROC gave area under the curve of 0.96, 80-83%
clinical sensitivity and 96-100% clinical specificity. This new ultrasensitive,
multiplexed assay for PTHrP and fragments is promising for clinical diagnosis,
prognosis and therapeutic monitoring from early to advanced stage cancer
patients and to examine underlying mechanisms of PTHrP overproduction.
Chapter 4 describes a novel 16-electrode immunoarray set-up for
simultaneous detection of upto 8 cancer protein biomarkers to aid in identifying
aggressive from indolent forms of prostate cancer. The system consists of a twochannel reaction chamber and a two-channel detection chamber for detection of
4 protein biomarkers on each channel. The protein panel includes; PSA, vascular
endothelial growth factor-D (VEGF-D), pigment epithelial derived factor (PEDF),
25

insulin growth factor-1 (IGF-1), insulin growth factor binding protein-3 (IGFBP-3),
monocyte differentiation antigen CD-14 (CD14), V-Ets avian erythroblastosis
virus E26 oncogene homolog ETS-related gene (ERG), and Golgi membrane
protein 1 (GOLM-1); many of which are thought to be specific for aggressive
prostate cancer. Detection limit in the pM range was achieved for multiplexed
detection of the cancer biomarker proteins from as little as 5 μL. Measurements
of this panel of selected biomarkers will be tested with prostate cancer patient
samples in future to assess its diagnostic capability in discriminating aggressive
from indolent forms of prostate cancer.
Chapter 5 describes the importance of incorporating nanomaterials in
immunoassay. It also gives detailed description of the methods used in our
laboratory to functionalize magnetic beads with antibodies and enzyme labels for
ultrasensitive detection of protein analytes. In addition, it describes strategies for
characterizing the magnetic bead bioconjugates employed in chapters 2, 3 and 4.
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CHAPTER TWO
On-line Protein Capture on Magnetic Beads for Ultrasensitive
Microfluidic Immunoassays of Cancer Biomarkers

2.1 Abstract
Accurate, sensitive, multiplexed detection of biomarker proteins holds
significant promise for personalized cancer diagnostics. Here we describe the
incorporation of a novel on-line chamber to capture cancer biomarker proteins on
magnetic beads derivatized with 300,000 enzyme labels and 40,000 antibodies
into a modular microfluidic immunoarray. Capture and detection chambers are
produced from PDMS on machined molds and do not require lithography. Protein
analytes are captured from serum or other biological samples in the stirred
capture chamber on the beads held in place magnetically. The beads are
subsequently washed free of sample components, and wash solutions sent to
waste. Removal of the magnet and valve switching sends the magnetic bead–
protein bioconjugates into a detection chamber where they are captured on 8
antibody-decorated

gold

nanoparticle-film

sensors

and

detected

amperometrically. Most steps in the immunoassay including protein capture,
washing and measurement are incorporated into the device. In simultaneous
assays, the microfluidic system gave ultralow detection limits of 5 fg mL -1 for
interleukin-6 (IL-6) and 7 fg mL-1 for IL-8 in serum. Accuracy was demonstrated
by measuring IL-6 and IL-8 in conditioned media from oral cancer cell lines and
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showing good correlations with standard ELISAs. We also adapted this analyte
capture strategy to detect a panel of biomarkers associated with oral mucositis;
an inflammatory lesion of oral mucosa caused by high-dose chemotherapy
and/or radiation that is especially prevalent during oral cancer treatment. The
target proteins involved in the pathobiology of oral mucositis include IL-6, IL1-β,
tumor necrosis factor (TNF-α) and C-reactive protein (CRP). Ultralow detection
limits of 10-40 fg mL-1 were achieved for multiplexed detection of these proteins
in 5 μL serum (2.5–10 zmol). Accuracy was verified by agreement of
immunoassay results with ELISA values in oral cancer patients undergoing
radiation therapy. This approach may lead to rapid, low-cost estimates of
projected risk for severity of oral mucositis in cancer patients to enable improved
therapeutic management. The on-line capture chamber facilitates rapid,
sensitive, repetitive protein separation and measurement in 30 min in a semiautomated system adaptable to multiplexed detection of virtually any protein.

2.2 Introduction
Molecule-based early cancer diagnoses promise to improve treatment
outcomes and patient survival rates.1,2 Current cancer diagnostics often rely on
biopsies, observing symptoms or lesions, or in vivo imaging. These approaches
depend on finding a tumor, making early detection difficult and possibly
compromising therapy outcomes. Screening for cancer without detecting tumors
can be based on assays of body fluids for cancer biomarker proteins to provide
an instantaneous record of a patient’s disease status. 2-5 For translation to the
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clinic, measurement devices for biomarker proteins should be accurate,
sensitive, cheap and preferably capable of point-of-care (POC) use. For reliable
diagnoses of cancers, it will be essential to measure panels of biomarker proteins
rather than single proteins for the best prediction efficiency.2, 6
Existing methods for measuring protein biomarkers including enzyme
linked immunosorbent assay (ELISA),7 magnetic bead-based assays2,8 and liquid
chromatography-mass spectrometry (LC-MS)9 are currently too expensive, time
consuming, and technically complex for multiplexed POC protein determinations
in clinical samples. Arrays based on optical,10,11 electrochemical12-16 or
nanotransistor17 detection have been developed to overcome some of these
limitations.6, 18 In reality, selected detection approaches can already achieve the
high sensitivity and accuracy necessary for clinical applications, but complexity,
cost and to a lesser extent multiplexing issues hold back clinical applications.
Microfluidics can improve immunoassay speed, cost and multiplexing.18, 1923

For example, an integrated microfluidic system recently reported for clinical

diagnosis of HIV and syphilis detects antibodies to the disease vectors at clinical
levels.10 This chip used optical detection to analyze 1 μL of whole blood within 20
min in clinics in the developing world. However, improvements in integrated
microfluidic systems still need to address multiplexing and other complexity
issues.
We have developed modular microfluidic systems to facilitate fast
multiplexed detection of proteins in biomedical samples.12,24,25 These devices
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feature a sensor array coated with gold nanoparticle (AuNP)-antibody conjugates
in a poly(dimethylsiloxane) (PDMS) microchannel interfaced to a syringe pump
and sample injector. Paramagnetic beads loaded with multiple detection
antibodies and horseradish peroxidase (HRP) enzyme labels are used to capture
protein analytes from sample solutions in small vials to provide detection of
biomarker proteins in serum down into the low fg mL -1 range.25 Accuracy and
diagnostic utility of these microfluidic arrays was demonstrated by measuring four
biomarker proteins in oral cancer patient serum samples.
While useful for diagnostics, the above system would benefit from simpler
operation for clinical and POC screening. Herein we report incorporation of an
on-line protein capture chamber in the modular microfluidic system. We used
magnetic beads coated with ~40,000 antibodies and ~300,000 HRP labels, and
validated the new system for simultaneous immunoassays of two proteins. The
capture chamber features an oval PDMS channel equipped with a tiny stir bar
sandwiched between two transparent poly(methyl methacrylate) (PMMA) plates
(Figure 2.1A). The bioconjugated magnetic beads and protein samples are
incubated in the chamber for on-line protein capture. After washing the beads
and sending the wash to waste, the protein-magnetic beads are directed into the
microfluidic detection chamber housing the 8-sensor AuNP array. This new
design allows semi-automated ultrasensitive assays to be completed in the
microfluidic device within 30 min. Nanostructured sensors combined with
massively labeled magnetic detection beads provided simultaneous assays with
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detection limits (DLs) of 5 fg mL-1 for IL-6 and 7 fg mL-1 for IL-8 in serum, similar
to DLs for off-line manual protein capture. In a four-protein multiplexed
measurement of IL-6, IL-1β, TNF-α and CRP, detection limits of 10-40 fg mL-1
were achieved in 5 μL serum. Accuracy and diagnostic utility of the arrays was
demonstrated by correlating the levels of these proteins in conditioned media for
oral cancer cell lines and serum from head and neck cancer patients with
standard ELISA.

2.3 Experimental Section
2.3.1 Chemicals and Materials
Screen-printed carbon arrays with 8 700 μm dia. sensors were from
Kanichi Research (UK). ʟ -glutathione reduced (GSH, 99%), gold (III) chloride
trihydrate

(HAuCl4·3H2O,

99.9%),

sodium

borohydride

(99%),

poly(diallyldimethylammonium chloride) (PDDA, MW 100,00-200,000, 20%),
bovine serum albumin (BSA), 1-(3-(Dimethylamino)propyl)-3-ethylcarbodiimide
hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHSS) were from Sigma.
Hydrogen peroxide (H2O2, 30%) was from Fisher. The poly(dimethoxy)silane
(PDMS) kit was from Dow Corning. Buffer pH 7.4 phosphate saline (PBS) was
0.01 M in phosphate, 0.14 M NaCl, 2.7 mM KCl. Tween-20 and hydroquinone
(HQ, ≥ 99%) were from Sigma-Aldrich. Streptavidin-coupled superparamagnetic
beads (1 μm, Dynabeads) and biotinylated horseradish peroxidase (HRP) were
from Invitrogen. All solutions were prepared with water purified by a Hydro water
purification system to 18 MΩ•cm.
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2.3.2 Antibodies and Proteins
Tumor Necrosis Factor (TNF-α) Duoset (catalog # DY210), Human
CReactive Protein (CRP) Duoset (catalog # DY1707), Interleukin-1β (IL-1β)
Duoset (catalog # DY201), monoclonal Human IL-6 Antibody (Ab1, clone no.
6708), human IL-6 biotinylated polyclonal antibody (Ab2, goat IgG), monoclonal
human CXCL8/IL-8 antibody (Ab1, clone no. 6217), human CXCL8/IL-8
biotinylated polyclonal Antibody (Ab2, goat IgG), protein standards, and ELISA
kits were from R&D systems.

2.3.3 Human Serum Samples and Conditioned media
Human serum samples were collected from patients undergoing high-dose
radiation therapy for H&N cancer at the Neag Comprehensive Cancer Center,
University of Connecticut Health Center (UCHC), USA. The study protocol was
IRB approved and written Informed Consent of participants was obtained prior to
sample collection. All samples were stored at or below -80 oC until use. Serum
samples were assayed directly and in selected cases spiked with biomarker
proteins for validation tests. Conditioned media from known oral cancer and
control cell lines26,27 were supplied by the National Institute of Dental and
Craniofacial Research (NIDCR), NIH, Bethesda, MD.

2.3.4 Instrumentation
Amperometric measurements were done at ambient temperature with a
CHI 1040 electrochemical workstation. The modular microfluidic immunoarray
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system (Figure 2.2) incorporates an on-line protein capture chamber (Figure
2.1A) upstream of an 8-sensor detection device (Figure 2.1B) that we reported
previously.12 The capture chamber features an internal layer of flexible PDMS
prepared on a machined template to have an oval hole sandwiched in between
two flat, machined PMMA plates (Figure 2.1A). When bolted tightly together, this
assembly forms an oval cylindrical channel 1.5 mm wide and 100 ± 2 μL in
volume housing a tiny magnetic stir bar (Figure 2.2A). Flow out of this channel
can be directed to waste or to the detection chamber by a switch valve system.

Figure 2.1: Components of (A) capture chamber in which target proteins are
captured on-line from the sample and (B) detection chamber that houses the 8electrode array.

The detection chamber is a PMMA-supported PDMS slab, with
rectangular channel 1.5 mm wide, 2.8 cm long and 63 ± 2 μL volume placed on
top of an 8-sensor gold nanoparticle-antibody coated screen-printed carbon array
(Figure 2.1B).12 The top PMMA plate features ports to connect 0.2 mm i.d. PEEK
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tubing at inlet and outlet. The detection chamber has a 0.6 mm dia. hole for
inserting a Ag/AgCl reference wire and 0.2 mm dia. hole for a Pt wire counter
electrode that both run along the entire length of the detection channel (Figure
2.1B). A syringe pump (Harvard, no. 70 4504) was connected to 2 switch valves
via sample injector (Rheodyne, 9725i) using 0.2 mm i.d. tubing (Figure 2.2).
These 2 valves enable changing the direction of flow from reaction chamber to
waste or to the detection chamber.

Figure 2.2: Photographs of microfluidic system for on-line protein capture and detection
using magnetic beads. (A) Capture chamber in which target proteins are captured online from the sample by heavily labeled HRP-antibody-magnetic beads to form proteinbead bioconjugates. These are washed, and then flowed into the detection chamber (B)
in the modular microfluidic system (C). The magnet (D) traps bioconjugate beads in the
channel during injection of sample and washing, and is removed for transfer of beads to
the detection chamber.
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2.3.5 Preparation of Ab2-magnetic particle -HRP (Ab2-MP-HRP)
Biotinylated secondary antibodies (Ab2) and biotinylated HRP labels were
attached onto the 1 μm diameter streptavidin-coated superparamagnetic beads
(MPs) as previously described.25 Briefly, 20 μL of MP (10 mg mL-1) were washed
three times with 0.1% BSA in PBS pH 7.4 and then reconstituted with 80 μL of
0.1% BSA in PBS pH 7.4. 40 μL of biotinylated-Ab2 (20 μg mL-1) and 80 μL of
biotinylated-HRP (2.5 mg mL-1) were then simultaneously added to the MP
dispersion to link biotin to streptavidin. The reaction was done at 37°C for 25 min
with slow tilt rotation in 1.5 mL microcentrifuge tubes. Ab 2-MP-HRP conjugates
were separated magnetically, using an Invitrogen DynaMag-spin magnet,
washed three times with 0.1% BSA in PBS pH 7.4 to remove unbound Ab 2 and
HRP, reconstituted with 200 μL of 0.1 % BSA in PBS and stored at 4°C until use.
From enzyme activity assays, the number of horseradish peroxidase
labels per MP was estimated to be 321,000 (± 23,000) using 2,2’-Azino-bis(3Ethylbenzthiazoline-6-Sulfonic acid) as a reactant.12,28 The average number of
Ab2 per MP was estimated by difference, from the amount left in solution, to be
38,000 (±7,000) using the bicinchoninic acid assay (BCA) kit.12,29,30

2.3.6 Array Preparation and Characterization
Glutathione-decorated gold nanoparticles (GSH-AuNPs) with diameter 5.0
± 2 nm were prepared by reduction of gold (III) chloride trihydrate salt using
sodium borohydride as reported previously.31 The screen-printed carbon
electrode was modified by electrostatic layer-by-layer deposition. Briefly,
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poly(diallyldimethylammonium chloride) (PDDA), a polycation was deposited on
the electrodes. The array was then washed and AuNPs deposited to increase
electroactive surface area and amplify the electrochemical signal of the arrays.
Primary antibodies (Ab1) were attached onto the GSH-AuNPs on the array via
EDC-NHSS amidization overnight. The electrode array was washed and
incubated with 2% BSA in PBS for 1 hr to block non-specific binding (NSB). A
fresh AuNP-antibody array is inserted into the detection module for each assay.

2.3.7 On-line protein analyte capture and detection
The general strategy is illustrated in Figure 2.3. 40 μL of Ab2-MP-HRP (1
mg mL-1 MPs) was added to 120 μL of 20 mM PBS, pH 7.4. This dispersion was
then loaded into the 100 μL sample loop and injected at 100 μL min -1 into the
capture chamber. 5 μL of protein analyte was diluted in calf serum and then
loaded into the sample loop and injected into the chamber. A magnet bar (N55
neodymium magnet) was placed on top of the chamber before sample was
injected to trap Ab2-MP-HRP. After the capture chamber was filled with sample,
flow was stopped and incubation was allowed for 30 min using the tiny stir bar for
mixing.
The resulting protein-Ab2-MP-HRP conjugates were then washed with
PBS-Tween 20. Flow was then stopped and protein-Ab2-MP-HRP conjugates in
the reaction chamber were re-dispersed in the PBS-Tween 20 by removing the
magnet. The valve was switched, and protein-Ab2-MP-HRP was then pumped
into the detection chamber. After the protein-Ab2-MP-HRP conjugates filled the
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detection chamber as evidenced by the red-brown color of MPs, flow was
stopped and incubation was done for 15 min for capture of the beads by
antibodies on the sensors. The array was then washed sequentially with
PBSTween20 and 1 mM HQ in PBS. Amperometric detection was done at -0.2 V
vs Ag/AgCl by injecting a mixture of 1 mM HQ and 100 μM H2O2 at 100 μL min-1
into the detection chamber via the sample loop.

Figure 2.3: Conceptual strategy for ultrasensitive amperometric detection by
microfluidic immunoarray. Protein analytes are captured on-line on Ab2-MP-HRP
bioconjugates in capture chamber. The protein-Ab2-MP-HRP is then magnetically
separated and washed in the chamber before being transported into the
detection chamber.
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During incubation in the detection chamber, the direction of flow from
capture chamber can be sent to waste, so that the next sample can be loaded for
capture with Ab2-MP-HRP. Thus, both protein capture on sample 2 and detection
on sample 1 can be done simultaneously to shorten assay time. Ideally, after the
measurement of the first sample, the analysis time is ~30 min.
For multiplexed detection, a mixture of 20 μL of Ab2-MP-HRP bioconjugate
for each analyte reconstituted with 120 μL of PBS was loaded into the 100 μL
sample loop and injected into the reaction chamber, followed by injection of a
mixture of either two proteins (IL-6 and IL-8) or four proteins (IL-6, IL-1β, TNF-α
and CRP) diluted in calf serum for standard calibrations. The procedure above
was then used for simultaneous detection of the oral cancer biomarkers and oral
mucositis biomarkers. All assay parameters were optimized for high sensitivity
and

high

signal-to-noise

ratio.

Control experiments

employed

the full

immunoassay procedure without antigen, and the response reflects the sum of
residual non-specific binding and direct reduction of hydrogen peroxide.

2.4 Results
2.4.1 Array Characterization
The detection module of the system incorporates screen-printed carbon
arrays

coated

with

5

nm

GSH-AuNPs

on

ultrathin

under-layers

of

poly(diallyldimethylamine) (PDDA) into a 63 μL microfluidic channel.12 Tapping
mode AFM images of uncoated carbon array sensors revealed a rough surface
featuring hills and valleys with mean surface roughness of 17 ± 0.8 nm (Figure
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2.4A). AFM images of array sensors with successively deposited layers of
poly(diallyldimethyl amine) (PDDA) and 5 nm GSH-AuNPs, revealed nearly
complete coverage of the underlying layer resulting in decreased mean surface
roughness of 14.5 ± 1.2 nm (Figure 2.4B). AFM showed broader globular
features after the immobilization of Ab1 on the array (Figure 2.4C), with mean
surface roughness slightly decreased to 12.4 ± 0.9 nm. The globular features are
characteristic of immobilized primary antibody on the AuNP underlayer. 31 The
electrochemical surface area after coating with AuNPs was estimated to be 2.53
(±0.26) × 10-3 cm2 using cyclic voltammetry of 1 mM ferrocyanide and RandlesSevcik equation.12

Figure 2.4: High resolution tapping mode AFM images of one of the array sensor
electrodes of (A) bare screen printed carbon, (B) Carbon/PDDA/GSH-AuNPs and
(C) Carbon/PDDA/GSH-AuNPs/Ab1.

2.4.2 Immunoarray Calibration
We chose IL-6 and IL-8 as test analyte proteins because they are
established biomarkers for oral, breast, prostate, and colorectal cancer. 32 IL-6 is
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a 20 kDa cytokine implicated in inflammation, acute phase reaction, growth
regulation and differentiation of cells.33 Average concentration of IL-6 in serum of
a healthy individual is < 6 pg mL-1 while in patients with oral cancer it ranges from
20 to over 1000 pg mL-1.34 IL-8 is an 8 kDa cytokine involved in inflammatory
response, with serum levels in healthy individuals at ≤13 pg mL-1 compared to
20-1000 pg mL-1 or more in cancer patients.35
The microfluidic on-line capture system was first optimized for individual
solutions of pure IL-6 and IL-8 in undiluted calf serum, a good surrogate for
human serum in immunoarrays.36 A key to achieving the best sensitivity and DLs
is minimization of non-specific binding (NSB). For this purpose, the antibody
coated array was incubated with 2% BSA for 1 hr prior to insertion in the
detection chamber and all washing steps include 0.05% Tween-20. Optimization
of surface concentrations of Ab1 on the sensors and secondary antibody (Ab2) on
the MP are also critical. Best performance was obtained using 100 μg mL-1 Ab1
for attachment to sensors, and 20 μg mL-1 Ab2 for attachment to MPs.
MPs with attached HRP labels and antibodies for IL-6 or IL-8 were
reconstituted in PBS, loaded into the sample loop, and injected into the capture
chamber. Their positions are easily followed by their red-brown color. With the
beads held in the capture chamber by a magnet, samples containing IL-6 or IL-8
were injected, and flow was stopped when the sample completely filled the
capture chamber. After incubation to capture the analyte proteins on the beads
and subsequent washing, the magnet is removed and flow is switched so that the
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protein-bioconjugate beads are transported to the detection chamber. Again flow
is stopped when the beads fill the detection chamber, and the beads are
captured by the second set of antibodies on the sensors. Following protein
capture and washing with PBS-Tween 20, a mixture of hydrogen peroxide to
activate HRP and hydroquinone as mediator is then injected via the sample loop
to develop the amperometric peaks (Figure 2.5A and C). A fresh 8-electrode
array was inserted into the detection chamber for each sample, and this can be
done while protein capture of the sample is occurring.
Using this protocol, peak currents increased linearly from 39 to 5,000 fg
mL-1 for IL-6 and 9 to 2,500 fg mL-1 for IL-8. Peaks with no analyte protein
(controls) are caused by a combination of direct reduction of hydrogen peroxide
and NSB of the labeled magnetic particles on the array. Excellent array-to-array
reproducibility is illustrated by the small error bars. The sensitivity of the
immunoarray was 4.7 μA mL [fg protein]-1 cm-2 for IL-6 and 2.0 μA mL [fg
protein]-1 cm-2 for IL-8 in undiluted calf serum.
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Figure 2.5: Amperometric responses for individual standard solutions of IL-6 and
IL-8 in undiluted calf serum at -0.2 V vs. Ag/AgCl developed by injecting a
mixture of 1 mM HQ and 0.1 mM H2O2 for (A) IL-6 and (C) IL-8, also showing
calibration plots for (B) IL-6 and (D) IL-8 standards. Error bars represent standard
deviations (n=8) for the eight electrodes of a single immunoarray.

NSB background can only result from residual NSB from the MPs having
no captured analyte. The extent of NSB was compared to that of off-line capture
in a small test tube using analyte-free controls (Figure 2.6A). There were no
observable differences in peaks produced by on-line and offline protocols,
showing that NSB is minimized to about the same extent by on-line and off-line
capture methods. Reproducibility was also tested for 0 and 5 pg mL -1 IL-6 (Figure
2.6B) and IL-8 (Figure 2.6C) by running the immunoassays on different days with
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different arrays. Relative standard deviation of the measurements for the two
concentrations was <4 % confirming good array-to-array and day-to-day
reproducibility.

Figure 2.6: Amperometric signals for (A) on-line vs off-line capture protocol for
control, (B) individual standard solutions of IL-6 and (C) IL-8 in undiluted calf
serum at -0.2 V vs Ag/AgCl developed by injecting a mixture of 1 mM HQ and 0.1
mM H2O2 on different days with different arrays.

2.4.3 Determination of the cross-reactivity of the analytes
The immunosensor was also used to assess antibody cross reactivity
using 5 pg mL-1 of IL-6 and IL-8. The immunoarrays were tested for cross
reactivity of the protein with BSA and nonspecific antibodies before doing
multiplexed detection. In these experiments, the arrays were coated with BSA
and both IL-6 and IL-8 primary antibodies, however the Ab2-MP-HRP-protein
conjugate flown into the detection chamber were conjugated with only one type
of protein. The amperometric measurements were recorded by injecting the
mixture of 1 mM HQ and 0.1 mM H2O2. Amperometric responses for the cross
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reactivity of the protein with non-specific antibodies is illustrated in Figure 2.7.
Minimum cross reactivity between the analyte and non-specific antibodies was
observed. Cross reactivity between IL-8 (protein analyte) with IL-6 capture
antibodies was 3 ± 2% (Figure 2.7A) whereas the cross reactivity between IL-6
(protein analyte) with IL-8 capture antibodies was 4 ± 1% (Figure 2.7B) and
considered to be within acceptable limits for simultaneous detection.
For multiplexed detection, specificity of the protein analyte was tested first
before obtaining the calibration curves. IL-6 capture antibodies were spotted on
the first four electrodes while IL-8 capture antibodies on the last four electrodes.
A mixture of 10 pg mL-1 IL-6 and 6 pg mL-1 IL-8, were mixed and injected into the
reaction to be captured with Ab2-MP-HRP conjugates for both IL-6 and IL-8. After
30 min incubation in the reaction chamber, the protein-Ab2-MP-HRP conjugate
was washed and dispensed onto the electrodes housed in the detection
chamber. Amperometric signals were recorded by injecting a mixture of 1 mM
HQ and 0.1 mM H2O2. Figure 2.7C shows the amperometric differences between
the response for the IL-6 on the first four electrodes and IL-8 on the last four
electrodes indicating high selectivity.
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Figure 2.7: Cross reactivity of the analyte with non specific antibodies. The array
was coated with BSA, IL-8 and IL-6 primary antibodies. (A) 5 pg mL-1 IL-6 and (B)
5 pg mL-1 IL-8 was injected and captured by the conjugate before being flown
into the detection chamber. (C) Determination of specificity of the protein analyte
on a single array. The first four electrodes show the amperometric response for
IL-6 while the last four electrodes show the amperometric response for IL-8.

2.4.4 Detection of IL-6 and IL-8 in mixtures
For simultaneous detection of IL-6 and IL-8, capture antibodies for each
protein were attached to four spots on the array (Figure 2.7C). Bioconjugate
beads for IL-6 and IL-8 were combined, reconstituted in PBS, loaded into the
sample loop, and injected into the reaction chamber, followed by injection of a
mixture of IL-6 and IL-8. Incubation, washing, transport to the detection chamber,
and detection were done as described above for the single protein standards.
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Figure 2.8: Amperometric responses for standard protein mixtures in undiluted
calf serum at -0.2 V vs Ag/AgCl developed by injecting a mixture of 1 mM HQ
and 0.1 mM H2O2 for (A) IL-6 and (C) IL-8, also showing calibration plots for (B)
IL-6 and (D) IL-8. Error bars represent standard deviations (n=4) for the four IL-6
or IL-8 antibody-modified electrodes on a single immunoarray.
The peak currents increased linearly from 5 to 2,500 fg mL-1 for IL-6 and 7
to 3,750 fg mL-1 for IL-8 (Figure 2.8). Lower concentrations represent DLs,
measured as three times the average standard deviation plus the zero protein
control. The sensitivity of the immunoarray was 4.51 μA mL [fg protein] -1 cm-2 for
IL-6 and 4.45 μA mL [fg protein]-1 cm-2 for IL-8 in undiluted calf serum.
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2.4.5 Oral Mucositis Biomarkers
Assays were also designed to accurately measure normal serum
biomarker levels as well as levels in patients undergoing oral cancer therapy.
Reported mean serum levels of healthy individuals for IL-6, IL-1β, and TNF-α are
10-30 pg mL-1, and 30 μg mL-1 for CRP. Serum levels before radiation therapy in
patients with oral cancer were reported to increase to 20-190 pg mL-1 for IL-6, IL1β and TNF-α, and ≥30 μg mL-1 for CRP.37,38
Primary antibodies for each protein were attached to two of the 8electrodes on the array. HRP-labeled magnetic beads with antibodies for IL-6,
TNF-α, CRP, and IL-1β were combined, re-dispersed in PBS, and injected as a
mixture into the reaction chamber, followed by injection of a mixture of the four
protein standards. All steps including incubation, washing, transport to detection
chamber and detection were done as described above for oral cancer
biomarkers. Binding studies related to the four protein analytes showed
acceptably low cross-reactivity for all antibodies (Figure 2.9).
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Figure 2.9: Duplicate responses measured simultaneously for (A) control mixture
of 0 fg mL-1 for IL-6, TNF-α, CRP and IL-1β, and (B) standard mixture of 18 fg
mL-1 IL-6, 12 fg mL-1 TNF-α, 15 fg mL-1 CRP, and 22 fg mL-1 IL-1β, illustrating
reproducibility and selectivity.

Calibration data for the target proteins are shown in Figure 2.9.1.
Detection limits (DLs) were 18 fg mL-1 for IL-6, 10 fg mL-1 for TNF-α, 15 fg mL-1
for CRP and 40 fg mL-1 for IL-1β for multiplex detection. Representative
amperometric responses for multiplexed detection (Figure 2.9.1A,C,E,G)
demonstrate high sensitivity in the pg/mL to low fg/mL range. Excellent
reproducibility is illustrated by the small error bars obtained for calibration curves
(Figure 2.9.1B,D,F,H), which were linear over 3 orders of magnitude
concentration.
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Figure 2.9.1: Amperometric responses for standard protein mixtures in 5-fold
diluted calf serum for (A) IL-6, (C) TNF-α, (E) CRP, and (E) IL-1β, developed by
injecting a mixture of 1 mM HQ and 0.1 mM H2O2 at -0.2 V vs. Ag/AgCl and the
corresponding calibration plots for (B) IL-6, (D) TNF-α, (F) CRP, and (H) IL-β.

2.4.6 Assay Validation
2.4.6.1 Assay Validation with Conditioned Media from Oral Cancer Cells
Oral cancer or head and neck squamous cell carcinoma (HNSCC) is the
sixth most common cancer in the developed world.39 High mortality of HNSCC is
related to frequent diagnoses at advanced stages.40,41 IL-6 and IL-8 are
associated with HNSCC, and hence accurate monitoring of their levels in patients
holds promise for early detection and therapeutic monitoring.
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Figure 2.9.2: Correlation plots of immunoarray assay results for conditioned
media of HaCat, HN12, HN13 and Cal27 cell lines vs. standard ELISA assays for
(A) IL-6 and (B) IL-8. Error bars represent standard deviations for the
immunoarray for n=4, and where not apparent are smaller than the point size.

To establish method accuracy, we used the microfluidic immunoarray to
analyze levels of IL-6 and IL-8 in conditioned media from populations of HNSCC
cell lines. Samples (5 μL) were diluted in PBS prior to injection into the capture
chamber. Good accuracy of the immunoarray is illustrated by linear correlation
plots with standard ELISA (Figure 2.9.2). The plots had slopes close to 1.0 (1.00
± 0.01 for IL-6 and 0.83 ± 0.01 for IL-8) and intercepts close to zero (-0.592 ±
13.4 for IL-6 and 0.458 ± 0.29), confirming good correlation. Figure 2.9.2 shows
comparative results for IL-6 and IL-8 in these samples by on-line capture
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immunoassays and standard ELISA. Cancer cell lines HN12, HN13 and Cal27
secreted large amounts of IL-6 and IL-8 (>1,000 pg mL-1), while immortalized
HaCaT cells established from normal cancer-free epidermal cells showed low
levels.

2.4.6.2 Assay validation with Human Serum Samples from H&N Cancer
Patients
In order to validate accuracy, we used the microfluidic array to measure
the levels of IL-6, TNF-α, and IL-1β simultaneously in ten serum samples from
head and neck cancer patients undergoing radiation therapy. For patient samples
CRP had to be measured separately due to its very high concentration in oral
cancer patient serum.37 For CRP, only 8 of the samples were analyzed as two of
them had CRP levels well above our linear range after our standard dilution
protocol, and amounts of sample were limited. In addition, CRP ELISA results
were from a single sample run because of limited sample amounts. Serum
samples collected on day 14 of radiation (1, 2, 3), day 35 of radiation (4, 5, 6, 7)
and 21 days post-radiation (8, 9, 10) were used for these accuracy validation
studies. Samples (5 μL) were diluted 30-fold in PBS prior to injection into the
assay device to bring concentrations into the linear range of the calibrations.
Several patient samples were spiked with different concentrations of standards to
augment accuracy assessment and analytical recovery of the assay. By spiking
the patient samples with 50, 100, 200, and 500 pg/mL of IL-6, TNF-α, and IL-1β
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standards, a wider range of concentrations of the proteins was obtained for more
representative correlation plots vs. ELISA. Good correlation of our results with
those obtained from standard single-protein ELISA measurements are illustrated
using bar graphs (Figure 2.9.3A).
Correlation was also assessed by linear plots of our immunoarray results
vs. single protein ELISAs. Strong correlation between two assays is indicated by
slopes approaching 1.0 and intercepts near 0. For this small sample set (≤ 10),
linear plots resulted in slopes and R2-values close to 1 and intercepts near 0 for
all target proteins suggesting relatively good correlation for all the biomarker
proteins (Figure 2.9.3B). The correlation plot slope for CRP (0.78) is a bit smaller
than that of other proteins. This may be due to high levels of the protein in the
μg/mL range requiring 1 million-fold serial dilutions that may generate volumetric
errors, in addition to the fact that we have only one ELISA assay point for each
sample for CRP. Nevertheless, as with all target proteins, CRP microfluidic
immunoassay results gave self-consistent values for individual samples that were
similar to ELISA values for most of the samples (Figure 2.9.3A).
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Figure 2.9.3: (A) Immunoarray and ELISA assay results from serum samples of
Head and neck cancer patients for IL-6, TNF-α, CRP, and IL-1β. S1-S4
corresponds to patient samples spiked with 50, 100, 200, and 500 pg/mL
respectively. (*) corresponds to values below the detection limits of ELISA and
(#) corresponds to values above the dynamic range of the microfluidic
immunoarray. (B) Linear correlation plots of immunoarray results against those
from individual ELISAs for human serum samples from cancer patients for IL-6,
TNF-α, CRP, and IL-1β. ELISA assays for CRP represent a single trial.

2.5 Discussion
Results described above demonstrate that the modular microfluidic
system featuring on-line capture of protein biomarkers onto massively multilabeled magnetic beads can accurately detect two protein cancer biomarkers in
serum with high sensitivity and ultralow DLs. The MPs have high surface area to
volume ratio here enabling attachment of 300,000 HRP labels and 40,000
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antibodies to provide extremely efficient protein capture 42 as well as high
sensitivity. Magnetic bead position is controlled magnetically in the on-line
capture chamber for rapid binding of proteins, washing, and delivery to the
detection chamber.
Sensitivities in undiluted calf serum from slopes of the calibration curves
were 4.5 μA mL [fg protein]-1 cm-2 for both IL-6 and IL-8. In contrast, assays
using a similar microfluidic device with no capture chamber and off-line protein
capture on beads with 400,000 HRP labels in simultaneous assays of 4 oral
cancer proteins gave sensitivities of 5.9 μA mL [fg protein] -1 cm-2 for IL-6 and 6.8
μA mL [fg protein]-1 cm-2 for IL-8 in serum.25 The slight decrease in sensitivity for
the present on-line capture system can be attributed to fewer HRP labels used in
Ab2-MP-HRP. DLs of 5 fg mL-1 for IL-6 and 7 fg mL-1 for IL-8 for the on-line
capture system were slightly better than the 10 fg mL-1 for both IL-6 and IL-8 in
the earlier 4-protein off-line capture assay.25
Thus, the new on-line protein capture chamber incorporated into the
earlier microfluidic detection system exhibited comparable sensitivity and about
2-fold better DLs from slopes of the calibration curves were 4.5 μA mL [fg
protein]-1 cm-2 for both IL-6 and IL-8. In contrast, assays using a similar
microfluidic device with no capture chamber and off-line protein capture on beads
with 400,000 HRP labels in simultaneous assays of 4 oral cancer proteins gave
sensitivities of 5.9 μA mL [fg protein]-1 cm-2 for IL-6 and 6.8 μA mL [fg protein]-1
cm-2 for IL-8 in serum.25 The slight decrease in sensitivity for the present on-line
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capture system can be attributed to fewer HRP labels used in Ab2-MP-HRP. DLs
of 5 fg mL-1 for IL-6 and 7 fg mL-1 for IL-8 for the on-line capture system were
slightly better than the 10 fg mL-1 for both IL-6 and IL-8 in the earlier 4-protein
offline capture assay.25 Thus, the new on-line protein capture chamber
incorporated into the earlier microfluidic detection system exhibited comparable
sensitivity and about 2-fold better DLs.
Very good accuracy of the assay system was confirmed by the correlation
of immunoarray results on conditioned media for oral cancer cell lines with ELISA
assays (Figure 2.9.1). Assays were done using 5 μL of conditioned media diluted
in PBS to fit the dynamic range of the immunoassay. Selectivity was confirmed
by accurate simultaneous detection of IL-6 and IL-8 in the conditioned cell media
that also contains hundreds of other proteins, many at relatively high
concentrations. In addition, the immunosensor gave good reproducibility as
demonstrated by small array-to-array standard deviations (Figure 2.8) suggesting
suitability for future clinical applications.
Inclusion of the on-line protein capture module provides a more automated
strategy compared to the earlier device that required off-line capture since
capture and washing are done in the microfluidic system, not manually as
previously.12,25 In the new system, most immunoassay steps are incorporated
into the microfluidic device, requiring only loading of reagents, samples and wash
solutions by the operator. The assay requires 30 min, which is less than 50 min
for the off-line capture assay25 and much less than standard ELISA (>5 hrs)43
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and other commercial detection methods. Thus, assay time and level of
automation begins to approach the needs of POC applications,6,44 but further
simplification of reagent addition will be required. The system has multiplexing
capability for up to 8 proteins at attomolar levels with DLs 100-1,000 fold better
than ELISA and commercial multiprotein bead assays, which have DLs of 1-10
pg mL-1 for many proteins.2, 5,45

2.6 Summary
In summary, we have fabricated and validated a modular microfluidic
system featuring novel on-line capture of analyte proteins on magnetic beads to
detect multiple cancer biomarker proteins. PDMS chambers are fabricated on
machined molds, so that no lithography is needed. They are coupled to
inexpensive commercial components so the system can be accessible to virtually
any

biomedical

laboratory.

Proof-of-concept

was

established

by

fast

ultrasensitive, selective, reproducible detection of two proteins in biologically
relevant mixtures. Partial automation and short analysis time suggest promise for
clinical diagnosis of cancer and therapeutic monitoring, although further
simplification is desirable. On-line capture on magnetic beads is also promising
for integration into other low-cost microfluidic systems.
Preliminary correlation analysis of patient sample protein levels assayed in
our work vs. standard metrics of oral mucositis severity suggested a strong
correlation with IL-6, but results are inconclusive due to the limited number of
samples. An ongoing related study by some of us (RVL, LAC, DEP) utilizing a
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wider range of samples established tentative correlations with IL-6 and CRP as
biomarkers for oral mucositis (unpublished data).
Future plans include assessing larger cohorts of patient samples at
varying stages of therapy. This approach may ultimately lead to accurate, lowcost, rapid estimates of projected risk of oral mucositis in cancer patients,
enabling improved therapeutic management. For example, human keratinocyte
growth factor-1 (palifermin) is recommended for the prevention of oral mucositis
in patients receiving autologous stem cell transplants.46 However, this treatment
is expensive, requires intravenous infusion, and is typically not indicated for the
patient projected to develop only mild clinical mucositis. The development of
such biomarkers to accurately predict who will develop severe mucositis can
enable such expensive interventions for mucositis to be selectively used in a
cost-effective manner. In turn, this would facilitate optimal delivery of cancer
therapy and improve patient prognosis.

2.7 References
1.

Etzioni, R.; Urban, N.; Ramsey, S.; McIntosh, M.; Schwartz, S.; Reid, B.;
Radich, J.; Anderson, G.; Hartwell, L., The case for early detection. Nat. Rev.
Cancer 2003, 3, 243-52.

2.

Rusling, J. F.; Kumar, C. V.; Gutkind, J. S.; Patel, V., Measurement of
biomarker proteins for point-of-care early detection and monitoring of cancer.
Analyst 2010, 135, 2496-511.

65

3.

Hanash, S. M.; Pitteri, S. J.; Faca, V. M., Mining the plasma proteome for
cancer biomarkers. Nature 2008, 452, 571-9.

4.

Kulasingam, V.; Diamandis, E. P., Strategies for discovering novel cancer
biomarkers through utilization of emerging technologies. Nat. Clin. Pract.
Oncol. 2008, 5, 588-99. 5, 588-599.

5.

Lilja, H.; Ulmert, D.; Vickers, A. J., Prostate-specific antigen and prostate
cancer: prediction, detection and monitoring. Nat. Rev. Cancer. 2008, 8, 26878.

6.

Gubala, V.; Harris, L. F.; Ricco, A. J.; Tan, M. X.; Williams, D. E., Point of
care diagnostics: status and future. Anal. Chem. 2012, 84, 487-515.

7.

Kingsmore, S. F., Multiplexed protein measurement: technologies and
applications of protein and antibody arrays. Nature Rev. 2006, 5, 310-20.

8.

Beveridge, J. S.; Stephens, J. R.; Williams, M. E., The use of magnetic
nanoparticles in analytical chemistry. Ann. Rev. Anal. Chem. 2011, 4, 251
73.

9.

Hawkridge, A. M.; Muddiman, D. C., Mass spectrometry-based biomarker
discovery: toward a global proteome index of individuality. Ann. Rev. Anal.
Chem. 2009, 2, 265-77.

10. Chin, C. D.; Laksanasopin, T.; Cheung, Y. K.; Steinmiller, D.; Linder, V.;
Parsa, H.; Wang, J.; Moore, H.; Rouse, R.; Umviligihozo, G.; Karita, E.;
Mwambarangwe, L.; Braunstein, S. L.; van de Wijgert, J.; Sahabo, R.;

66

Justman, J. E.; El-Sadr, W.; Sia, S. K., Microfluidics-based diagnostics of
infectious diseases in the developing world. Nature med. 2011, 17, 1015-9.
11. Lee, H. J.; Wark, A. W.; Corn, R. M., Microarray methods for protein
biomarker detection. Analyst 2008, 133, 975-83.
12. Chikkaveeraiah, B. V.; Mani, V.; Patel, V.; Gutkind, J. S.; Rusling, J. F.,
Microfluidic electrochemical immunoarray for ultrasensitive detection of two
cancer biomarker proteins in serum. Biosens. Bioelectron.2011, 26, 4477-83.
13. Rusling, J. F., Nanomaterials-based electrochemical immunosensors for
proteins. Chem. Record. 2012, 12, 164-76.
14. Rusling, J.; Munge, B.; Sardesai, N.; Malhotra, R.; Chikkaveeraiah, B., 2013.
Nanoscience based electrochemical sensors and arrays for detection of
cancer

biomarker

proteins,

In:

Crespilho,

F.N.

(Ed),

Nanobioelectrochemistry. Springer-Verlag, Berlin-Heidelberg, pp. 1-26.
15. Wang, J., Nanoparticle-Based Electrochemical Bioassays of Proteins.
Electroanalysis 2007, 19, 769-776.
16. Wei, F.; Liao, W.; Xu, Z.; Yang, Y.; Wong, D. T.; Ho, C. M., A Bio-abiotic
Interface Constructed by Nanoscale DNA-Dendrimer and Conducting
Polymer for Ultra-sensitive Bio-molecular Diagnosis. Small 2009, 5, 1784-90.
17. Patolsky, F.; Zheng, G.; Lieber, C. M., Nanowire-based biosensors. Anal.
Chem. 2006, 78, 4260-9.
18. Chin, C. D.; Linder, V.; Sia, S. K., Commercialization of microfluidic point
ofcare diagnostic devices. Lab chip 2012, 12, 2118-34.
67

19. Gervais, L.; de Rooij, N.; Delamarche, E., Microfluidic chips for point-of-care
immunodiagnostics. Adv. Mater. 2011, 23 (24), H151-76.
20. Manz, A.; Harrison, D. J.; Verpoorte, E. M. J.; Fettinger, J. C.; Paulus, A.;
Lüdi, H.; Widmer, H. M., Planar chips technology for miniaturization and
integration of separation techniques into monitoring systems: Capillary
electrophoresis on a chip. J. Chromatogr. A 1992, 593, 253-258.
21. Pan, Y.; Sonn, G. A.; Sin, M. L.; Mach, K. E.; Shih, M. C.; Gau, V.; Wong, P.
K.; Liao, J. C., Electrochemical immunosensor detection of urinary lactoferrin
in clinical samples for urinary tract infection diagnosis. Biosens. Bioelectron.
2010, 26, 649-54.
22. Wang, J.; Ahmad, H.; Ma, C.; Shi, Q.; Vermesh, O.; Vermesh, U.; Heath, J.,
A self-powered, one-step chip for rapid, quantitative and multiplexed
detection of proteins from pinpricks of whole blood. Lab chip 2010, 10, 3157
62.
23. Whitesides, G. M., The origins and the future of microfluidics. Nature 2006,
442, 368-73.
24. Krause, C. E.; Otieno, B. A.; Latus, A.; Faria, R. C.; Patel, V.; Gutkind, J. S.;
Rusling, J. F., Rapid microfluidic immunoassays of cancer biomarker
proteins

using

disposable

inkjet-printed

gold

nanoparticle

arrays.

ChemistryOpen 2013, 2, 141-5.
25. Malhotra, R.; Patel, V.; Chikkaveeraiah, B. V.; Munge, B. S.; Cheong, S. C.;
Zain, R. B.; Abraham, M. T.; Dey, D. K.; Gutkind, J. S.; Rusling, J. F.,
68

Ultrasensitive detection of cancer biomarkers in the clinic by use of a
nanostructured microfluidic array. Anal. Chem. 2012, 84, 6249-55.
26. Jeon, G. A.; Lee, J. S.; Patel, V.; Gutkind, J. S.; Thorgeirsson, S. S.; Kim, E.
C.; Chu, I. S.; Amornphimoltham, P.; Park, M. H., Global gene expression
profiles of human head and neck squamous carcinoma cell lines. Int. J.
Cancer. 2004, 112, 249-58.
27. Sriuranpong, V.; Park, J. I.; Amornphimoltham, P.; Patel, V.; Nelkin, B. D.;
Gutkind, J. S., Epidermal growth factor receptor-independent constitutive
activation of STAT3 in head and neck squamous cell carcinoma is mediated
by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine
system. Cancer Res. 2003, 63, 2948-56.
28. Pütter, J., 1983. Methods of Enzymatic Analysis 3. In: Becker, R.,
Bergmeyer, H.U. (Eds.),VerlugChemie, Deerfield Beach, FL. pp. 286-293.
29. Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia, A. K.; Gartner, F. H.;
Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.; Olson, B. J.; Klenk, D. C.,
Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150,
76-85.
30. Wiechelman, K. J.; Braun, R. D.; Fitzpatrick, J. D., Investigation of the
bicinchoninic acid protein assay: identification of the groups responsible for
color formation. Anal. Biochem. 1988, 175, 231-7.
31. Mani, V.; Chikkaveeraiah, B. V.; Patel, V.; Gutkind, J. S.; Rusling, J. F.,
Ultrasensitive immunosensor for cancer biomarker proteins using gold
69

nanoparticle film electrodes and multienzyme-particle amplification. ACS
nano 2009, 3, 585-94.
32. Xie, K., Interleukin-8 and human cancer biology. Cytokine Growth Factor
Rev. 2001, 12, 375-91.
33. Deckert,

F.;

Legay,

F.,

Development

and

validation

of

an

IL-6

immunoreceptor assay based on surface plasmon resonance. J. Pharm.
Biomed. Anal. 2000, 23, 403-12.
34. Riedel, F.; Zaiss, I.; Herzog, D.; Gotte, K.; Naim, R.; Hormann, K., Serum
levels of interleukin-6 in patients with primary head and neck squamous cell
carcinoma. Anticancer Res. 2005, 25, 2761-5.
35. Gokhale, A. S.; Haddad, R. I.; Cavacini, L. A.; Wirth, L.; Weeks, L.; Hallar,
M.; Faucher, J.; Posner, M. R., Serum concentrations of interleukin-8,
vascular endothelial growth factor, and epidermal growth factor receptor in
patients with squamous cell cancer of the head and neck. Oral Oncol. 2005,
41, 70-6.
36. Yu, X.; Munge, B.; Patel, V.; Jensen, G.; Bhirde, A.; Gong, J. D.; Kim, S. N.;
Gillespie, J.; Gutkind, J. S.; Papadimitrakopoulos, F.; Rusling, J. F., Carbon
nanotube amplification strategies for highly sensitive immunodetection of
cancer biomarkers. J. Am. Chem. Soc. 2006, 128, 11199-205.
37. Jablonska, E.; Piotrowski, L.; Grabowska, Z., Serum Levels of IL-1b, IL-6,
TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer. Pathol. Oncol.
1997, 3, 126-129.
70

38. Brailo, V.; Vucicevic-Boras, V.; Lukac, J.; Biocina-Lukenda, D.; Zilic-Alajbeg,
I.; Milenovic, A.; Balija, M., Salivary and serum interleukin 1 beta, interleukin
6 and tumor necrosis factor alpha in patients with leukoplakia and oral
cancer. Med. Oral Patol. Oral Cir. Bucal. 2012, 17, e10-5.
39. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A., Cancer statistics, 2011: the
impact of eliminating socioeconomic and racial disparities on premature
cancer deaths. CA Cancer J. Clin. 2011, 61, 212-36.
40. Horowitz, A. M.; Alfano, M. C., Performing a death-defying act. J. Am. Dent.
Assoc. 2001, 132, 5s-6s.
41. Siegel, R.; Naishadham, D.; Jemal, A., Cancer statistics, 2012. CA Cancer J.
Clin. 2012, 62, 10-29.
42. Mani, V.; Wasalathanthri, D. P.; Joshi, A. A.; Kumar, C. V.; Rusling, J. F.,
Highly efficient binding of paramagnetic beads bioconjugated with 100,000 or
more antibodies to protein-coated surfaces. Anal. Chem. 2012, 84, 10485
91.
43. Findlay, J. W.; Smith, W. C.; Lee, J. W.; Nordblom, G. D.; Das, I.; DeSilva, B.
S.; Khan, M. N.; Bowsher, R. R., Validation of immunoassays for bioanalysis:
a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2000, 21,
1249-73.
44. Soper, S. A.; Brown, K.; Ellington, A.; Frazier, B.; Garcia-Manero, G.; Gau,
V.; Gutman, S. I.; Hayes, D. F.; Korte, B.; Landers, J. L.; Larson, D.; Ligler,
F.; Majumdar, A.; Mascini, M.; Nolte, D.; Rosenzweig, Z.; Wang, J.; Wilson,
71

D., Point-of-care biosensor systems for cancer diagnostics/prognostics.
Biosens. Bioelectron. 2006, 21, 1932-42.
45. Ward, A. M.; Catto, J. W.; Hamdy, F. C., Prostate specific antigen: biology,
biochemistry and available commercial assays. Ann. Clin. Biochem. 2001,
38, 633-51.
46. Lalla, R. V.; Bowen, J.; Barasch, A.; Elting, L.; Epstein, J.; Keefe, D. M.;
McGuire, D. B.; Migliorati, C.; Nicolatou-Galitis, O.; Peterson, D. E.; RaberDurlacher, J. E.; Sonis, S. T.; Elad, S., MASCC/ISOO clinical practice
guidelines for the management of mucositis secondary to cancer therapy.
Cancer 2014, 120, 1453-61.

72

CHAPTER THREE
Ultrasensitive Multiplexed Detection of Parathyroid Hormone
related Peptides (PTHrP) Using Gold Nanoparticle Immunoarrays
3.1 Abstract
Parathyroid hormone-related peptide (PTHrP) is a paraneoplastic protein
recognized as the major causative agent of humoral hypercalcemia of
malignancy (HHM). Independent of hypercalcemia, PTHrP has also been
implicated in tumor progression and metastasis of a variety of human cancers.
Conventional PTHrP detection methods such as immunoradiometric assay
(IRMA) lack the sensitivity required to measure its levels prior to the development
of hypercalcemia and pose potential health hazards due to the use of radioactive
isotope labels. Here, we describe the first ultrasensitive multiplexed assay to
measure intact PTHrP1-173 isoform as well as its fragments consisting of Nterminal and C-terminal peptides. We employed a microfluidic system featuring a
small microfluidic chamber for on-line capture of the peptides from serum onto
magnetic beads labeled with multiple copies of peptide-specific antibodies and
signal-transducing enzyme labels. The magnetic bead-peptide conjugate was
then washed and sent to a detection chamber housing antibody-modified 8electrode array fabricated by ink-jet printing of gold nanoparticles. Limits of
detection (LOD) of 3 fg mL-1 (~1000 fold lower than IRMA) were achieved for
simultaneous detection of PTHrP isoforms and fragments within 30 min. Very
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good correlation was observed with IRMA (n=57); r2=0.99 using PTHrP1-173 and
1-86 fragment. Analysis of the sample data by ROC resulted in area under the
curve of 0.96, 80-83% sensitivity and 96-100% specificity. Our study suggests
that PTHrP1-173 isoform is the predominant circulating form of PTHrP. This new
ultrasensitive, rapid, multiplexed, assay for PTHrP isoforms and fragments can
aid in diagnosis, prognosis and therapeutic monitoring of cancer patients from
early to advanced stages and help examine underlying mechanisms of PTHrP
overproduction.

3.2 Introduction
The existence of a parathyroid hormone (PTH)-like factor was first
postulated by Albright over 60 years ago1 as a humoral factor responsible for the
development of hypercalcemia in cancer patients and later described as humoral
hypercalcemia of malignancy (HHM).2 The true nature of this PTH-like factor
remained elusive as it escaped detection by immunoassays using antibodies
raised against PTH3,4 but could be detected using bioassays based on activation
of the PTH receptor.5,6 This lead to the cloning and characterization of this PTHlike factor now known as parathyroid hormone-related peptide (PTHrP)7,8 and to
the development of specific immunoassays.9,10
Human PTHrP comprises of three isoforms of 139, 141 and 173 amino
acids proteins through alternative mRNA splicing at the 3’end. 11 All the isoforms
have identical amino acid sequence through residue 139 and undergo
posttranslational cleavage generating N-terminal, mid-region and C-terminal
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peptides with distinct physiological functions. Because of the N-terminal
homology, PTHrP exerts PTH-like actions in bone and kidney by binding and
activating the same guanylyl nucleotide-binding (G) protein-linked receptor
(PTH1R) causing hypercalcemia.12,13
In addition to its PTH-like effect leading to hypercalcemia, PTHrP display
properties distinct from those of PTH.14,15 PTHrP is widely expressed in both
normal and cancerous human tissues.16,17 It acts as endocrine, autocrine,
paracrine, or intracrine factor in a vast range of important physiological roles
including normal skeletal development, placental calcium transport, smooth
muscle relaxation, and mammary gland development.15 Circulating levels of
PTHrP have also been shown to correlate with disease progression in a variety
of human cancers including breast, prostate, melanoma e.t.c 18-21 and
development of bone metastasis in several studies. 22-24 However, PTHrP in the
vast majority of cases can only be detected in the blood circulation when
hypercalcemia

develops.9,10

Once

hypercalcemia

is

present,

there

is

approximately 50 percent chance the patient will die within 30 days. 25 Therefore,
current PTHrP assays are limited to confirming the humoral origin of
hypercalcemia but cannot provide tools for early detection of PTHrP producing
tumors prior to the development of hypercalcemia. Early detection requires
PTHrP assays with much higher sensitivity and/or specificity. Conventional
assays for measuring the level of PTHrP in cancer patients include
radioimmunoassay (RIA) and immunoradiometric assay (IRMA).9,10,26 Despite the
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specificity, ease of isotope conjugation and stability against interference from
assay components such as serum/plasma, there are still several drawbacks
limiting IRMA use in a normal clinical setup. The high energy isotopes employed
such as 125I pose substantial health hazard, require expertise to handle, and strict
regulations to be met. These isotopes also have a short halflife which translates
to a short shelf-life of the labeled reagents.27,28 Assays that do not require
radioisotope labeling such as enzyme linked immunosorbent assay (ELISA),29
immunofluorometric assay30 and mass spectrometry27,31 have been developed for
PTHrP detection. However, most of these assays lack the sensitivity required to
measure levels of PTHrP in cancer patients early in the disease process prior to
the development of hypercalcemia. Furthermore, none of these assays are
designed to measure specific PTHrP isoforms and in particular the human
specific PTHrP1-173 isoform.
In this chapter, we adapted a recently developed novel semi-automated
modular microfluidic device32 to detect peptides for the first time. The microfluidic
system first delivers the sample to a capture chamber, where enzyme-labeled
magnetic beads equipped with antibodies capture each target peptide. Then, the
beads are washed and delivered to 8-sensor gold immunoarray (~$0.2 per
array)33 decorated with a second set of antibodies that recognize and bind the
magnetic

bead-bound

target

peptides.

The

peptides

are

measured

simultaneously by activation of enzyme labels and electrochemical detection.
Intact PTHrP isoforms as well as N- and C-terminal fragments were detected
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simultaneously in serum. LOD of 3 fg mL-1 was achieved, which is 1000 fold
lower than any commercially available PTHrP assay. Good correlation between
the microfluidic immunoarray and IRMA results in cancer patients’ serum/plasma
demonstrates the diagnostic potential of the new assay. To the best our
knowledge, this is the first ultrasensitive assay to simultaneously detect the intact
PTHrP isoforms and its fragments.

3.3 Experimental Section
3.3.1 Chemicals and Materials
Horseradish peroxidase (HRP), sterile filtered bovine calf serum, Tween20, bovine serum albumin (BSA), gold (III) chloride trihydrate (HAuCl4·3H2O,
99.9%),

sodium

borohydride

(99%),

tetrocylammonium

bromide,

3-

mercaptopropionic acid (MPA), 1-dodecane thiol, poly(amic acid), 1-(3(Dimethylamino)propyl)-3-ethylcarbodiimide

hydrochloride

(EDC),

Nhydroxysulfosuccinimide (NHSS) and hydroquinone (HQ, ≥ 99%) were from
Sigma-Aldrich. Hydrogen peroxide (H2O2, 30%) was from Fisher. Kapton FPC
film

(127

mM

thick)

poly(dimethoxy)silane
Immunoreagents

was

(PDMS)

(monoclonal

purchased
kit

was

from

American

purchased

antibodies,

from

polyclonal

Durafilm.
Dow

The

Corning.

antibodies,

BSA,

horseradish peroxidase (HRP)) were dissolved in pH 7.4 phosphate saline buffer
(PBS, 5.9 mM Na2HPO4, 3.9 mM NaH2PO4, 2.7 mM KCL, 120 mM NaCl). 400
mM EDC and 100 mM NHSS were dissolved in water immediately before use. All
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solutions were prepared with 18 MΩ·cm water purified through use of a Hydro
water purification system (Durham, NC, USA).

3.3.2 PTHrP peptides and Antibodies
Intact PTHrP 1-173 was produced from cDNA encoding the PTHrP 1-173
isoform. Human PTHrP fragments 1-33, 151-169, 140-173 were purchased from
Sheldon Biotechnology Center (McGill University). Human recombinant PTHrP 186 expressed in E.Coli was purchased from Sigma-Aldrich. Monoclonal
antibodies M45 (IgM) and PA158 (IgG) were raised against PTHrP1-33;
monoclonal antibody PA104 (IgG) was raised against PTHrP 140-173;
monoclonal antibody PA6 (IgG) was raised against PTHrP 151-169, PA104,
PA158. All monoclonal antibodies were purified by affinity chromatography
(Medilabs, Quebec) and found highly specific with no cross reactivity with PTH
and other unrelated peptides.34 The bioactivity of these monoclonal antibodies
was tested previously both in vitro and in vivo. Polyclonal antibodies against
human PTHrP 1-173 (IgY lots 3103 and 3104) were raised in chicken and
purified commercially (Genway Biotech, San Diego, CA).

3.3.3 Immunoradiometric assay (IRMA) for PTHrP
We used a commercial PTHrP assay for correlation purposes (PTHrP
RUO, Active® IRMA catalog # DSL8100 Beckman Coulter Canada Inc, Montreal,
Canada). This IRMA has been previously described to measure PTHrP in various
cancer stages and to establish normal control values. It uses an N-terminal
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monoclonal antibody raised against PTHrP1-40 and a mid-region monoclonal
antibody raised against PTHrP 57-80. It has a sensitivity of 3 pg/mL and linearity
up to 2100 pg/mL. Internal controls were made using pooled patients samples
and conditioned media from PTHrP producing cells lines. The inter-assay
variability was 4.4% and the intra-assay variability was 4.7%, according to the
manufacturer’s specifications. Normal values obtained from 40 healthy
volunteers range from 0-15 pg/mL.

3.3.4 Human Serum Samples
Human serum samples from 22 healthy subjects and 37 cancer patients
were obtained from McGill University Health Center. Samples were stored at or
below -80°C until analyzed.

3.3.5 Array Fabrication
Immunoarrays were fabricated from 4 nm dodecanethiol decorated gold
nanoparticles (AuNPs) on Kapton sheet as previously described using Dimatix
inkjet materials printer (Figure 3.1).33 Gold nanoparticle ink was prepared at 100
mg mL-1 in toluene and filtered using a 0.2 mm cutoff PTFE filter. The ink was
then injected into a Dimatrix cartridge for use in the Dimatrix Inkjet materials
printer. Upon printing, the electrode arrays were annealed 15 minutes at 200°C
to drive off the thiol layer. The arrays lightened in color indicating the loss of the
dodecane thiol layer and Au cores coalescing. Immediately after being annealed,
the arrays were returned to the Dimatrix Inkjet materials printer to print the
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poly(amic acid) insulation layer. The poly(amic acid) ink was prepared by diluting
the 10% (m/m) poly(amic acid) solution in pure N-methyl-2-pyrrolidone (NMP) to
1% (m/m) and the adding the solution to a liquid crystal Dimatrix printer cartridge
immediately prior to use.

Figure 3.1: A photograph of Dimatix Inkjet Materials Printer from Fujifilm and
printed gold nanoparticles (AuNPs) arrays on surface of Kapton Sheet.

The electrode arrays were then cleaned in 0.18 M sulfuric acid, by cycling
potential between 1.5 and -0.2 V vs. saturated calomel electrode (SCE) to
remove gold oxide from the surface. The electrode arrays were coated with self
assembled monolayer (SAM) of mercaptopropionic acid (MPA) to introduce
carboxyl groups on the surface of the array. The surface carboxyl groups were
activated by freshly prepared EDC and NHSS to attach monoclonal antibodies
(Ab1) to array elements through amidization overnight. The arrays-modified with
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Ab1 were then washed with PBS-T20 to remove excess unbound Ab1 and
incubated with 2% BSA for 1 hr to minimize non-specific binding (NSB). The Ab1modified arrays were then fitted into the detection chamber for amperometric
measurement. A new array was employed for each measurement.

3.3.6 Derivatization of Magnetic Beads
Magnetic bead bioconjugates [tosyl-activated magnetic beads (MBs)Horseradish peroxidase (HRP)-Antibody (Ab2)] were prepared using as
previously described35 with slight modification to reduce the bead conjugate
preparation time from 42 to 24 hr. Briefly, tosylactivated magnetic beads (MB)
(0.2 mg) were washed 3x with sodium borate buffer (pH 9.5), then reconstituted
in 3 M ammonium sulfate + 0.1 M sodium borate buffer (volume 1:1).
Horseradish peroxidase (HRP) (3 mg) and polyclonal antibody (Ab 2) (0.8 mg)
were then simultaneously added to the dispersion and incubated at 37 ˚C for 18
hrs. The magnetic bead bioconjugates (HRP-MB-Ab2) were then washed with
PBS-T20 and reconstituted in 0.5% BSA at 37 ˚C for 6 hrs to block NSB. The
resulting beads were washed 3x with 0.1% BSA, reconstituted in 600 μL of 0.1%
BSA and stored at 4 ˚C. The number of Ab2 per MB was estimated to be (4–11)
×104 for different polyclonal antibodies for PTHrP using a protein assay kit
(Bicinchoninic acid assay, BCA).36 Activity assays showed that the number of
HRP per MB was (1.3-2.6) × 105 (Table 3.1).37
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Table 3.1: Characterization of Magnetic Bead Conjugate

3.3.7 Detection of PTHrP isoforms and fragments
The semi-automated microfluidic system was constructed as previously
reported32 (Figure 3.2) and electrochemical measurements were all done at room
temperature with a CHI 1040A eight-channel potentiostat at conditions optimized
for high sensitivity and low S/N. The capture and detection chamber were first
connected to the microfluidic system and subjected to a flow of PBS-T20 to block
for NSB. 30 μL of HRP-MB-Ab2 conjugate was reconstituted in 130 μL of 20 mM
PBS buffer (pH 7.4), loaded into the 100 μL sample loop and injected into the
capture chamber at 100 μL/min flow rate. 5 μL of PTHrP standard reconstituted
in 5x diluted calf serum was loaded into the sample loop and injected into the
capture chamber. HRP-MB-Ab2 conjugate were held in the capture chamber,
through use of a neodymium magnet positioned above the top PMMA plate, as
the peptide standard or serum/plasma sample was injected. For simultaneous
detection of N-terminal (1-33 or 1-86), and C-terminal peptides (151-169, 140173) or intact 1-173 isoform, 10 μL of HRP-MB-Ab2 conjugate for each peptide
was reconstituted in 130 μL of PBS buffer, loaded into the sample loop and
82

injected into the capture chamber followed by injection of a mixture of the three
standard peptides diluted in calf serum. Flow was then stopped, magnet removed
and incubation was allowed for 30 mins with stirring for the peptide to be
captured by HRP-MB-Ab2 conjugate.

Figure 3.2: Immunoarray set-up for on-line peptide capture: (A) microfluidic
device and (B) detection pathway.

The resulting peptide-Ab2-MB-HRP conjugates were washed by flushing
the capture chamber with PBS-T20 while holding the magnet bar on top of the
PMMA plate and then re-dispersed in PBS-T20. The direction of flow was
changed and the peptide-Ab2-MB-HRP conjugates were transported into the
detection chamber housing the Ab1-modified 8-electrode array. After peptide-Ab2MB-HRP conjugates filled the detection chamber, flow was stopped and
incubation was allowed for 15 mins for Ab 1 on the array to capture the bead
conjugate. Unbound bead conjugate was then washed off by resuming buffer
flow.
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To perform amperometric measurements, the arrays were further
subjected to a flow of buffer containing 1 mM hydroquinone in PBS for 4 mins.
The 8 electrodes of the array were then connected to the working electrode leads
of a CHI 1040 multi-potentiostat, and the Pt and Ag/AgCl wires were connected
to the counter and reference leads, respectively. Amperometric detection was
performed at -0.3 V vs Ag/AgCl by injecting a mixture of 1 mM hydroquinone and
0.1 mM hydrogen peroxide into the detection chamber via the sample loop at 100
μL/min. Hydrogen peroxide activates HRP on the peptide-Ab2-MB-HRP
conjugates to ferryloxy-HRP,

which,

in

turn

oxidizes hydroquinone to

benzoquinone. Signal is generated as benzoquinone is reduced through a 2electron transfer at the electrode surface.

3.4 Results
3.4.1 Single Peptide Detection
PTHrP generally undergoes post-translational proteolytic cleavage at
lysine or arginine residue to generate smaller biologically active N-terminal,
midregion and C-terminal peptide fragments.10,11 We therefore first designed
single peptide assays for N-terminal (1-33 & 1-86) and C-terminal fragments
(151-169 & 140-173) as well as intact PTHrP 1-173 isoform. PA158, PA6 &
PA104 were employed as capture antibody on the sensor elements while M45,
IgY3103 & IgY3104 were attached onto magnetic bead conjugate as detection
antibody (Table 3.2). Standards for the peptide fragments were prepared in 5x
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diluted calf serum as a surrogate for human serum.38 Control experiments
employed full immunoassay reagents without the peptide analyte.

Table 3.2: Antibody and Peptide Pairing for Sandwich Assay

To establish optimal conditions for the assays as well as to improve on
both the signal to noise ratio and sensitivity, antibody concentrations were first
optimized on the beads and sensors prior to obtaining calibration curves. Nterminal fragments (1-33 & 1-86) were paired with antibodies PA158 and MA45,
while the C-terminal fragments (151-169 & 140-173) were paired with antibodies
(PA6 & PA104) and (IgY3103 & IgY3104) (Table 3.2). We began with optimizing
the antibody concentrations on the magnetic beads keeping a consistent Ab 1
antibody concentration of 100 μg mL-1, and employing standard concentration of
0, 2.5, and 5 pg mL-1 for standard peptide fragments (of 151-169, 140-173, and
1-33). The optimal secondary antibody concentration was determined from the
greatest signal difference between the control and sample concentration for
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IgY3103 50 μg mL-1, for IgY3104 50 μg mL-1, and for M45 20 μg mL-1 (Figure 3.3
D,E,F).

Figure 3.3: Optimization of Ab1 and Ab2 concentration using a control and
standard concentrations of 2.5, 5 pg mL-1 for (A) PA104, (B) PA6, (C) PA158, (D)
IgY3103, (E) IgY3104, and (F) MA45. Optimal concentrations for both Ab 1 and
Ab2 are circled.

Once the secondary antibody concentration was confirmed for the
conjugate magnetic beads the optimal concentration of primary antibody on the
surface of arrays was established using a consistent optimized secondary
antibody concentration (IgY3103 50 μg mL-1, IgY3104 50 μg mL-1, and M45 20
μg mL-1) again employing standard concentrations of 0, 2.5, and 5 pg mL -1 for
standard peptide fragments (of 151-169, 140-173, and 1-33). The greatest signal
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difference between control and sample concentration indicated the optimal
primary antibody concentration to be 100 μg mL -1 for all monoclonal antibodies
(Figure 3.3 A,B,C).
Using the optimized concentrations of Ab1 and Ab2, calibration plots for the
individual peptide fragments were obtained (Figure 3.4). Control signals resulted
from a combination of NSB of the magnetic bead conjugate on the sensor
elements and direct reduction of hydrogen peroxide. Current density increased
linearly with log C for all the peptide fragments from 3 fg mL-1 to 16 pg mL-1. LOD
measured as three times the standard deviation above the control ranged from 35 fg mL-1 for all the peptides (Table 3.2). These LODs are 1000-fold better than
IRMA and commercial ELISA kits (3-5.5 pg mL-1). Good assay reproducibility is
indicated by the small error bars for the standard points in the calibration plot.
Sensitivities, obtained from the slope of the calibration plot, were dependant on
the peptide fragment size. For the smaller peptide fragments (1-33, 140-173 &
151-169), sensitivities were in the range of 1.98 – 2.12 μA cm-2 [log C]-1 while the
larger peptide fragments exhibited a much higher sensitivity (3.55 – 4.98 μA cm-2
[log C]-1) (Table 3.2).
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Figure 3.4: Responses for (A) 1-33 obtained at -0.3 V vs Ag/AgCl. Calibration
plots for PTHrP peptide fragments in 5x diluted calf serum: (B) 1-33, (C) 1-86, (D)
151-169, (E) 140-173 and (F) intact PTHrP 1-173 (n=8).

3.4.2 Multiplexed Peptide Detection
Based on the sensitivities observed during single peptide detection, the
larger peptide fragments (1-86 & 1-173) were selected for multiplexed detection
(Table 3.2). Employing the 8-electrode array, a sandwich assay was build up on
the first three electrodes for detection of 1-173 using PA104 and IgY3103, the
next three electrodes for detection of 1-86 using PA158 and MA45 and the last
two electrodes for detection of 1-173 using PA6 and IgY3104 (Figure 3.5A).
Magnetic bead conjugate (10 μL each) with MA45, IgY3103 and IgY3104 were
combined, dispersed in PBS and injected into the capture chamber via the
sample loop. A mixture of standards for 1-86 and 1-173 (volume ratio 1:2) was
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then introduced into the capture chamber with the aid of the magnet bar
positioned above the capture chamber. All steps, from washing the resulting
peptide-bead conjugate to amperometric detection, were performed as illustrated
above for single peptide detection. Prior to obtaining calibration plots, binding
studies were done to determine the specificity of the antibodies towards the
peptide fragments (Figure 3.5B). Minimal cross-reactivity was observed between
the antibodies for 1-173 and 1-86 peptide analytes.

Figure 3.5: A) Multiplexing strategy for the peptide fragments on a single 8electrode inkjet-printed AuNPs array. B) Representative amperometric response
for detection of a mixture of 1-173 and 1-86 on a single 8-electrode array.

Calibration plots for detection of a mixture of the peptides are shown in
Figure 3.6. Current density increased linearly with log C of the peptides from 3 fg
mL-1 to 12 pg mL-1. LODs were 4 fg mL-1 for 1-86, 6 fg mL-1 for 1-173 (PA104)
and 3 fg mL-1 for 1-173 (PA6). Excellent reproducibility is illustrated with small
error bars for the standards mixtures. In addition, combination of PA104 &
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IgY3104 and PA6 & IgY3103 exhibited similar sensitivity towards detection of
intact PTHrP1-173 isoform (4.49 vs 4.48 μA cm-2 [log C]-1) (Figure 3.6B & F).
This is consistent with the observations made during specificity (Figure 3.5B) and
the binding studies previously done by our collaborators.34

Figure 3.6: Amperometric responses for standard peptide mixtures in 5x diluted
calf serum at -0.3 V vs Ag/AgCl for (A) intact PTHrP 1-173 using PA104, (C) 1-86
peptide fragment (E) intact PTHrP 1-173 using PA6 and also showing calibration
plots for intact PTHrP 1-173 (B & F) and 1-86 fragment (D) (n=3).

3.4.3 Validation using Cancer serum samples
Serum and plasma samples from cancer patients and cancer-free
individuals were assayed and compared with IRMA results to validate accuracy.
The antibody used for 1-86 peptide binds all three PTHrP isoforms and their N90

terminal fragments. The antibody used for 1-173 binds PTHrP 1-173 and shorter
fragments such as 140-173 and 151-169.34 A significant difference in the PTHrP
levels between the healthy individuals and cancer patients was observed; 2sample t-test at the 95% confidence level confirmed great difference between the
two cohorts (P<0.001) (Table 3.3).

Table 3.3: Serum Samples Data

Cancer patient samples had larger amounts of PTHrP upto 90 pg mL -1
compared to healthy individuals (<10 pg mL-1, Figure 3.7A,B). Assays by the
immunoarray and IRMA gave similar levels of PTHrP; t test at the 95%
confidence level confirmed no significant difference between the two methods
(Figure 3.7C). Our assay detected PTHrP levels in all samples including 4 that
were undetectable by IRMA. Immunoarray results gave good linear correlation
plots with IRMA for all 57 samples (22 controls and 35 cancer subjects) with
slopes close to 1 (0.90 ± 0.02 for 1-86 & 0.82 ± 0.01 for 1-173), intercepts near 0
(1.33 ± 0.51 for 1-86 & 0.39 ± 0.28 for 1-173) and correlation coefficients of 0.99
(Figure 3.7D; Table 3.4). Values obtained with assay measuring intact PTHrP 1173 and its fragments (red) were only slightly lower than values obtained with the
assay recognizing all three isoforms and its fragments labeled as 1-86 (blue)
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suggesting that PTHrP 1-173 is the form of PTHrP in these samples (Figure
3.7C).

Table 3.4: Correlation plot table

Figure 3.7: Distributions of PTHrP levels in serum and plasma from cancer
patients (37) and cancer-free individuals (22) for (A) 1-86; (B) PTHrP 1-173; (C)
bar graph comparing IRMA and immunoarray (1-86 & 1-173) results for PTHrP
(n=12) and (D) correlation plot of IRMA and immunoarray data (1-86 & 1-173)
(n=57). Asterisk (*) denotes value below IRMA LOD.
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3.4.4 ROC Analysis
Analysis of the patient PTHrP data was also done using Receiver
Operating Characteristic (ROC) plots. ROC is commonly used in clinical tests to
determine the accuracy of the test and obtain cut-off values in diagnostic tests. In
ROC curves, sensitivity (true positive rate) is plotted against 100-specificity (false
positive rate) for different cut-off points. Each point on the ROC curve represents
a sensitivity/specificity pair corresponding to a particular decision threshold. A
test with perfect discrimination has a ROC curve that passes through the upper
left corner (100% sensitivity, 100% specificity).39 Therefore, the closer the ROC
curve is to the upper left corner, the higher the overall accuracy of the test. The
area under a ROC curve (AUC) quantifies the overall ability of the test to
discriminate between those individuals with the disease and those without the
disease. A truly perfect test with zero false positives and zero false negatives has
an AUC of 1.00.
For PTHrP (n=57) the ROC plot had AUC of 0.96 for the 1-86 fragment
assay and 0.94 the PTHrP1-173 assay (Figure 3.8). 1-86 fragments gave 80%
sensitivity and 100% specificity while intact PTHrP1-173 gave 82.9% sensitivity
and 95.5% specificity. The cancer vs. non-cancer cut-off PTHrP was 10.9 pg mL1

using the 1-86 assay and 8 pg mL-1 using the 1-173 assay, which is in

agreement with IRMA results. However, curves for individual peptides (Figure
3.8A) gave relatively similar sensitivity and specificity when using normalized,
mean values of the two peptides (Figure 3.8B).
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Figure 3.8: Receiver operating characteristic (ROC) curves for (A) serum assays
for 1-173 (red) with AUC 0.94, 95.5% specificity and 82.9% sensitivity & 1-86
(blue) with AUC 0.96, 100% specificity and 80% sensitivity; and (B) normalized
value for both 1-86 and 1-173 with AUC 0.96, 100% specificity and 80%
sensitivity.

3.5 Discussion
Results described above demonstrate development of the first assay for
simultaneous detection of PTHrP and its peptide fragments in serum/plasma
down to 3 fg mL-1. The 1 μm superparamagnetic beads with 250,000 HRP labels
and 120,000 antibodies (Ab2) per bead enabled high capture efficiency and
ultrahigh sensitivity to be achieved in 30 mins assays. 1-86 peptide assays
measured the level of all the three PTHrP isoforms (PTHrP1-139, 1-141 and 1173) and their fragments containing N-terminal end of the peptides while assay
using 1-173 measured the long isoform PTHrP1-173 and shorter fragments of it
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such as 140-173, 80-173 e.t.c in serum. A novel and interesting observation is
that circulating concentrations of the PTHrP 1-173 isoform and its fragments was
only slightly lower than the concentrations of all three isoforms and their
fragments suggesting that PTHrP 1-173 is the predominant circulating form of
PTHrP, a finding that requires further investigation in larger cohorts.
Sensitivities of the single-detection assays ranged from 2–5 μA cm-2 [log
C]-1. The highest sensitivities were obtained for peptide fragments 1-86 & 1-173,
which were used for multiplexed detection of patient samples. Assay results
revealed a significant difference between the levels of PTHrP in healthy
individuals (<10 pg mL-1) compared to cancer patients and our assays could also
detect PTHrP levels in all the samples (Figure 3.7). In agreement, ROC analyses
(Figure 3.8) gave 80-83% sensitivity and 96-100% specificity for clinical detection
of cancer. While the sample size is small and many more need to be analyzed,
results suggest a high potential of PTHrP 1-86, 1-173 immunoassay for early
stage cancer diagnostics.
Fragments of PTHrP are under investigation to determine their diagnostic
potential in variety of human cancers. Washam et al, identified N-terminal
fragment of PTHrP 12-48 as a plasma biomarker for breast cancer bone
metastasis with sensitivity of 91% and specificity of 93%.40 Using mass
spectrometry, PTHrP 12-48 was significantly elevated in plasma of breast cancer
patients with bone metastasis compared to controls without metastasis
(P<0.0001). Combination of a clinical serum marker N-telopeptide of type I
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collagen (NTx) with plasma PTHrP 12-48 greatly increased the diagnostic
specificity and accuracy (AUC=0.99). However, mass spectrometry is costly, time
consuming, and technically complex, and unlikely to be feasible for point-of-care
peptide assays. Our assay, on the other hand, can detect PTHrP levels using
both large and small fragment sizes at levels as low as 3 fg mL-1.
The microfluidic immunoarray offers a simple, rapid, low cost way to
simultaneously detect PTHrP peptide fragments. Inkjet printing technology offers
both a simple and elegant way to fabricate disposable low-cost sensor
electronics for the immunoarray. A single 8-electrode array cost ≈$0.2, and up to
56 arrays can be printed in a single run.33 Thus, ease of fabrication and utilization
of commercial components makes this approach accessible to virtually any
biomedical laboratory at low cost. Capture and detection chamber are made by
templating PDMS channels on machined aluminium molds to avoid lithography,
and mounted on hard plastic PMMA housings with inlet and outlet lines. The
microfluidic device requires only small sample volume (5 μL) and offers a degree
of automation and reliability to enhance reproducibility and throughput. These
advantages make the microfluidic immunoarrays a

promising tool for

development of sensitive, integrated, portable, clinical diagnostic devices in a
short time with minimal sample and reagent requirements.
In summary, we present above a novel approach for simultaneous
detection of isoforms of PTHrP in a single assay suitable for comparisons of
circulating forms. The assay permits accurate analysis of both normal and
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pathological clinical samples with numerous potential applications in pathologies
and physiological conditions in which PTHrP has been implicated. Results of
cancer patient samples support the diagnostic usefulness of such assays. This
technology is amenable at examining PTHrP overproduction in a variety of
cancer patients from early to late stages of disease.
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CHAPTER FOUR
Ultrasensitive Electrochemical Microfluidic Immunoarray for
Assessment of Aggressive vs Indolent forms of Prostate Cancer

4.1 Abstract
Prostate cancer is the most common cause of cancer-related death in
men in the US and throughout the world. Current practices for detection and
staging of prostate cancer often fall short in terms of sensitivity, specificity and
inability to distinguish between aggressive and indolent forms of prostate cancer.
These limitations lead to unnecessary treatments that adversely affect the
patients’ quality of life with minimal or no gain. Measurement of small panels of
molecular signature biomarkers in serum holds tremendous potential for cancer
diagnostics and personalized therapy. Here we describe a simple, low-cost,
modular microfluidic system for on-line capture and detection of prostate cancer
protein biomarkers. The protein panel includes PSA, vascular endothelial growth
factor-D (VEGF-D), pigment epithelial derived factor (PEDF), insulin growth
factor-1 (IGF-1), insulin growth factor binding protein-3 (IGFBP-3), monocyte
differentiation antigen CD-14 (CD14), V-Ets avian erythroblastosis virus E26
oncogene homolog ETS-related gene (ERG), and Golgi membrane protein 1
(GOLM-1), many of which are thought to be specific for aggressive prostate
cancer. The system features a 1 or 2-channel small chamber for on-line protein
capture from serum by magnetic beads labeled with many copies of analyte
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specific antibodies and signal-transducing enzyme labels, positioned upstream of
a 1 or 2-channel detection chamber housing a nanostructured 8 electrode sensor
array. Nanostructured commercial screen printed carbon arrays ($3) are fitted
into the microfluidic detection chamber to achieve high sensitivity. Ultralow
detection limit in the low fM range was achieved in a 45 mins assay while higher
detection limits in pM range was achieved in 25 mins assay for multiplexed
detection of the biomarker proteins. Measurements of this panel of selected
biomarkers will be tested with prostate cancer patient samples from US and
Ireland to assess its diagnostic capability in discriminating aggressive from
indolent forms of prostate cancer.

4.2 Introduction
Prostate cancer is the second most common cause of cancer-related
death and the most male non-cutaneous malignancy in US and Ireland.1 Recent
statistic from American Cancer Society2 and Irish Cancer Society3 demonstrate
that just as many men die from prostate cancer as women die from breast
cancer. In US alone 2.8 million men live with prostate cancer, 200,000 new
cancer cases are diagnosed every year and approximately 30,000 die each
year.2,4 In Ireland, more than 3,300 prostate cancer cases are diagnosed
resulting in more than 500 patient death each year.3 The lifetime risk of men
developing prostate cancer in these countries is 1 in 7 men. In a population with
increased longevity, it is likely that prostate cancer will become even more
clinically prevalent in future. This projected increase is a major public health
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concern, especially when there are dilemmas associated with both detection and
treatment of prostate cancer.4
Current practices for initial assessment of prostate cancer include prostate
specific antigen (PSA) blood test and digital rectal exam (DRE). 5,6 If either PSA
level is above 4 ng mL-1 or the DRE test is suspicious or abnormal, then the
patient undergoes transrectal ultrasound (TRUS) biopsy. These practices have
led to early detection of prostate cancer and improved the patient survival rate
and treatment outcomes. However, they have also led to inaccurate
assessments often resulting in unnecessary or unwarranted treatments that
adversely affect patient quality of life with little or minimal gain.7-9 PSA, for
example, has low specificity to prostate cancer as the levels are also elevated in
conditions such as benign prostatic hypertrophy (BPH), prostatitis, and
catheterization. In addition, PSA has limited predictive power and inability to
clearly distinguish aggressive forms of prostate cancer from indolent forms. 10-12
During DRE, the tip index finger only reaches a small area of the prostate gland,
and tumors in the anterior and medial lobes of the prostate may be undetectable.
Biopsy on the other hand is invasive, and again only a partial representation of
the entire prostate can be sampled and there is a chance of missing small but
significant areas. All these limitations have led to over-diagnosis and ultimately
over-treatment of the indolent forms of prostate cancer that would otherwise not
become clinically manifest over a patient’s lifetime or not result in cancer-related
death.8,9,13 Therefore, more strategies are needed to accurately detect and stage
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prostate cancer and most importantly to better stratify patients for appropriate
treatment options.
Measurement of a small panel of signature molecular biomarkers in serum
holds tremendous promise for future cancer diagnostics and personalized
therapy.14-16 Biomarker discovery research for prostate cancer has been the
focus of many laboratories across the world. The main aim is to identify new
biomarkers that can better detect prostate cancer and at the same time reduce
the number of unnecessary biopsy.17 Several protein biomarkers including
VEGF-D18,19, PEDF18,20,21, IGF-118, IGFBP-318, CD-1418, ERG22-24, and GOLM122 have recently been shown to be associated with prostate cancer. Oon et al,
for example, validated a panel of VEGF-D, PEDF, IGF-1, IGFBP-3 and CD-14 in
patients from the Irish Cancer Research Consortium. The biomarker panel was
validated with an AUC of 76.6%, and a sensitivity and specificity of 80% and 75%
respectively.18 Using a 2D-DIGE, PEDF and zinc-α2-glycoprotein (ZAG) have
been identified as serum markers for the progression of prostate cancer.20
However, conflicting findings have also been reported regarding correlation of the
levels of these biomarkers with severity of prostate cancer.25-27 Therefore, a
multiple biomarker based diagnostic assay needs to be conducted to ascertain
the correlation of these biomarkers to prostate cancer grade and their ability to
distinguish aggressive from indolent form of prostate cancer.
Our

laboratory recently developed

a

semi-automated

8-electrode

electrochemical microfluidic immunoarray for on-line capture and detection of
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upto 4 cancer protein biomarkers (Figure 4.1).28,29 Protein analytes were
captured on-line in a small microfluidic device from serum by heavily labeled
magnetic beads, magnetically separated, washed and re-dispersed in buffer prior
to introduction into a second microfluidic device, detection chamber. The
detection chamber houses primary antibody (Ab1)-modified array that sorts and
bind the protein-bead conjugate to complete the sandwich format. Protein
analytes were detected amperometrically by activation of the enzyme label.
Massively

labeled

magnetic

beads,

modular

microfluidic

platform,

and

nanostructured sensor enable rapid, ultrasensitive, simultaneous detection of
biomarker proteins in small volume serum samples (~5 μL).
In this chapter, we fabricated a novel 16-electrode electrochemical
microfluidic immunoarray for simultaneous detection of 8 prostate cancer protein
biomarkers (Figure 4.2). The protein panel includes PSA, PEDF, VEGF-D, ERG,
GOLM-1, CD-14, IGF-1 and IGFBP-3, many of which are thought to be
associated with aggressive prostate cancer.18-22 The microfluidic system features
a 2- channel capture chamber in which protein analytes are captured from serum
by heavily labeled magnetic beads upstream a 2-channel detection housing two
8- electrode Ab1-modified array. Capture chamber and detection chamber are
interfaced with an automated syringe pump, a manual injector and switching
valves. The protein analytes are captured and detected sequentially in the
channels. Detection limits in the fM range were obtained on the 8-electrode
system while higher detection limits in pM range were obtained on the 16108

electrode system by tailoring the assay time. Patient samples will be analyzed
and compared with standard ELISA to ascertain the accuracy of immunoarray
and also to determine the diagnostic utility of these protein markers in
distinguishing aggressive from indolent forms of prostate cancer.

4.3 Experimental Section
4.3.1 Antibodies & Proteins
Human Vascular Endothelial Growth Factor-D (VEGF-D) duoset (catalog#
DY622), Human Kallikrein 3/ Prostate Specific Antigen (PSA) duoset (catalog#
DY1344), Human Insulin Growth Factor Binding Protein 3 (IGFBP-3) duoset
(catalog# DY675), Human Insulin Growth Factor 1 (IGF-1) duoset (catalog#
DY291), Human monocyte Cluster of Differentiation 14 (CD-14) duoset (catalog#
DY383) and Human serpin F1/ Pigment Epithelial Derived Factor (PEDF) duoset
(catalog# DY1177-05) were from R&D Systems. All the duosets contain
monoclonal primary antibody, biotinylated-secondary antibody and recombinant
protein (antigen). Human Golgi membrane protein 1 (GOLM-1) [Biotinylated
Secondary Antibody clone 2D6 (catalog# TA700480), Purified Human Protein
(catalog# TP314745) and Capture Antibody clone 2F3 (catalog# TA600480)] and
Human ETS-related gene (ERG) [Biotinylated Secondary Antibody clone 5F12
(catalog# TA700176), Purified Human Protein (catalog# TP308093) and Capture
Antibody clone 8A9 (catalog# TA600177)] were from OriGene Technologies, Inc.
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4.3.2 Human Serum Samples
Human serum samples were collected from prostate cancer patients and
healthy individuals from George Washington University. The study protocol was
IRB approved and written Informed Consent of participants was obtained prior to
sample collection. All samples were stored at or below -80 0C until use. Serum
samples will be assayed directly and in selected cases spiked with biomarker
proteins for validation tests.

4.3.3 Chemicals & Materials
Screen printed carbon 8-sensor array chips were designed to our
specifications (700 μm) by Kanichi Research, Ltd (Manchester, UK). Sodium
borohydride (99%), poly (diallyldimethylammonium chloride) (PDDA, MW
100,000-200,000,

20%),

N-hydroxyxulfosuccinimide

(NHSS),

1-(3-

(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC), L-Glutathione
reduced (GSH, 99%), gold (III) chloride trihydrate (HAuCl4.3H2O, 99.9%),
Tween- 20, calf serum, lyophilized 99% bovine serum albumin (BSA) and
hydroquinone (HQ, ≥90%) were from Sigma Aldrich. Dynabeads® MyOne™
Streptavidin T1 and biotinylated-Horseradish peroxidase (HRP), enzyme label
were purchased from Life Technology. Hydrogen peroxide was from Fisher
Scientific and polydimethylsiloxane (PDMS) kit was from Dow corning. Tubing
and switching valves were from IDEX Health & Science. Immunoreagents
(monoclonal primary antibodies, BSA, biotinylated secondary antibodies and
biotinylated HRP) were dissolved in pH 7.4 phosphate saline (PBS) buffer (0.01
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M phosphate, 0.14 M NaCl, 2.7 mM KCl) unless otherwise noted. EDC and
NHSS were dissolved in water immediately before use. All solutions were
prepared with water purified by Hydro water purification system to 18mΩ.cm.

4.3.4 Preparation of Magnetic-bead Conjugates (Ab2-MP-HRP)
Biotinylated antibodies (Ab2) and biotinylated HRP were chemically
bonded onto 1 μm diameter streptavidin-coated super-paramagnetic particles
(MPs) as previously described in chapter two. The number of HRP labels per MP
ranged from 300,000-500,000 (±37,000) from enzyme activity assays. The
bicinchoninic acid assay (BCA) was used to estimate 40,000 -100,000 (± 15,000)
Ab2 per MP.28,29

4.3.5 Array Fabrication
Screen printed carbon sensors in the array were coated with sequential
layers of polycation PDDA and 5 nm GSH-AuNPs using layer-by-layer
electrostatic adsorption as previously reported in chapter two. 28,29 Surface
carboxyl groups on the GSH-AuNP layer were activated by freshly prepared EDC
and NHSS to attach primary antibodies (Ab1) to array elements through
amidization. The arrays were then washed and incubated with 2% BSA in PBS
for 1 hr to block non-specific binding (NSB). For amperometric measurements,
the Ab1-modified array was positioned in a detection chamber, which consisted of
a microfluidic channel with reference and counter wire electrodes. A new AuNPantibody array was used for each assay.
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4.3.6 Single Detection of Protein Biomarkers
The microfluidic system (Figure 4.1) was used in concert with Ab2-MPHRP detection labels and Ab1-decorated sensor arrays. Briefly, 40 μL of Ab2-MPHRP (1 mg mL-

1

MPs) was dispersed in 120 μL of 20 mM PBS pH 7.4, loaded

into a 100 μL sample loop and injected at 100 μL min -1 into the capture chamber.
Subsequently, 5 μL of protein analyte diluted in calf serum was loaded into the
sample loop and injected into the chamber. Once the capture chamber was filled
with sample, flow was stopped for 30 min with stirring in the chamber to facilitate
analyte capture. The protein-Ab2-MP-HRP conjugates were then washed,
dispersed in PBS-Tween-20, and a valve was switched to transport them into the
detection chamber. When protein-Ab2-MP-HRP conjugates filled the detection
chamber, flow was stopped for 15 min for capture of the conjugate on the Ab1modified sensor surfaces. Buffer flow was then resumed to remove any unbound
conjugate from the microfluidic channel.
The eight sensors in the array were connected to the leads of a
multipotentiostat while the Pt counter and Ag/AgCl reference wires were
connected to the appropriate CHI 1040A leads. To generate amperometric
peaks, a mixture of 1 mM HQ mediator and 0.1 mM H 2O2 was injected into the
microfluidic device through the 100 μL sample loop. Amperometric signals were
measured via the multipotentiostat with the array potential at -0.2 V vs. Ag/AgCl.
HRP on the antigen-Ab2-MP-HRP conjugates is activated by hydrogen peroxide,
resulting in the oxidized ferryloxy form of HRP. The electron mediator (HQ) then
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reduces the ferryloxy-HRP, regenerating HRP. The signal is developed by the
reduction of oxidized mediator (benzoquinone) at the sensor surface.

Figure 4.1: (A) Illustration of the microfluidic set up for on-line capture and
detection of cancer protein biomarkers. (B) Protein analytes are captured onto
the Ab2-MP-HRP in the capture chamber to form protein-bead bioconjugates. (C)
Amperometric signal generation by injecting a mixture of 1 mM HQ, electron
mediator, and 0.1 mM H2O2 into the detection chamber.

4.3.7 Multiplexed Detection of Protein Biomarkers
For multiplexed detection of the 8-panel protein cancer biomarkers, a
novel 16-electrode system was designed (Figure 4.2A). The system features a
two-channel detection chamber housing two 8-electrode array (Figure 4.2C) and
two-channel capture chamber with ports on the top poly (methylmethacrylate)
(PMMA) plate to hold the magnet bar (Figure 4.2B). Each reaction chamber
channel is 100 μL in size while the detection chamber channel is 70 μL in size.
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The system is connected to an automated syringe pump, switching valves and
manual injector to introduce reagents and sample.

Figure 4.2: (A) Photograph of the automated 16-electrode microfluidic system
featuring (B) a two-channel capture chamber with ports to hold the magnet bar
and (C) a two-channel detection chamber housing two 8-electrode arrays.

The protein panel was segregated into two groups consisting of the
proteins with low concentration in serum (PSA, ERG, IGF-1, VEGFD) and those
with high concentration in serum (GOLM-1, PEDF, IGFBP-3, CD-14) (Figure 4.3).
10 μL each of the magnetic bead conjugate for the first group were mixed and
reconstituted in 120 μL of PBS. The mixture of the magnetic bead conjugate was
introduced into the channel 1 of the capture chamber followed by introduction of
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a mixture of protein analytes. Incubation was then allowed for 10 min as the bead
conjugate and sample were introduced onto channel two. The protein-bead
conjugate was then washed and transferred onto the detection for additional 10
min incubation. Detection was performed as previously described on the 8electrode system.

Figure 4.3: Multiplexing strategy for the 8-panel protein on the 16-electrode
system. High and low concentration proteins in serum are assayed on separate
channels of the system.
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4.4 Results
4.4.1 Optimization of the Biomarker Panel
The microfluidic array was first optimized separately for all the 8-protein
panel in 5-fold diluted calf serum, a good surrogate for human serum. 30 Optimal
surface concentrations of antibody on each Ab2-MP-HRP conjugate were
established prior to obtaining calibration curves by comparing amperometric
responses between analyte standards and controls. Control experiments
featured the full immunoassay procedure without the protein analyte. Control
signals result from a combination of direct reduction of hydrogen peroxide and
NSB of the labeled bioconjugate beads on the sensors. To minimize NSB, 0.1%
BSA was used in the preparation of the magnetic particle bioconjugates, while
2% BSA was incubated on sensors for 1 hr prior to incorporation into the
microfluidic device. Further control of NSB was established by washing with PBS
Tween-20 in both capture and detection chamber.
Optimal concentration of Ab1 on the surface of the sensor arrays was
determined by varying concentrations of Ab1 from 25 to 100 μg mL-1 on the
arrays while keeping the concentration of Ab2 constant on the magnetic bead
conjugate. A control (5x diluted calf serum) and a sample (diluted protein
standard) were then run on the arrays with different concentrations of Ab1. The
concentration of Ab1 that resulted in the highest difference between control and
sample was selected as the optimal concentration of Ab 1 (Figure 4.4).
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Figure 4.4 A-H: Optimization of Ab1 and Ab2 concentration using a control and
standard concentrations of 2.5, 5 or 10 pg mL -1 for (A) CD-14 Ab2, (B) CD-14
Ab1, (C) IGFBP-3 Ab2, (D) IGFBP-3 Ab1, (E) ERG Ab2, (F) ERG Ab1, (G) GOLM
Ab2, and (H) GOLM Ab1. Optimal concentrations for both Ab1 and Ab2 are circled.

Similarly, the concentration of Ab2 was also optimized on the magnetic
bead conjugate. This was done by keeping the concentration of Ab 1 constant on
the surface of the array and varying the concentration of Ab 2 on magnetic beads
from 4.5 to 10 μg mL-1. A control and sample were run and the concentration of
Ab2 that gave the highest signal difference between the control and sample was
selected as the optimal concentration of Ab2 (Figure 4.4). The key factors that
play a role here are surface coverage and orientation of the antibodies on the
beads and sensor surface.
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Figure 4.4 I-P: Optimization of Ab1 and Ab2 concentration using a control and
standard concentrations for (I) IGF-1 Ab2, (M) IGF-1 Ab1, (J) PEDF Ab2, (N)
PEDF Ab1, (K) VEGF-D Ab2, (O) VEGF-D Ab1, (L) PSA Ab2, and (P) PSA Ab1.
Optimal concentrations for both Ab1 and Ab2 are circled.

4.4.2 8-Electrode System: Single Biomarker Detection
Using the above optimal conditions for Ab1 and Ab2, individual calibration
curves were developed for the 8-protein panel. Peak currents increased linearly
from 3 fg mL-1 to 15 pg mL-1 when these proteins were analyzed alone in 30 min
assay (Figure 4.5 A-H & I-N). Peaks without target analyte are caused by a
combination of direct peroxide reduction and non-specific adsorption of the
labeled magnetic particles on the electrode surface. Detection limits measured as
3 times the standard deviation above the control were 3 fg mL -1 for IGFBP-3, 88
fg mL-1 for ERG, 4 fg mL-1 for GOLM-1, 5 fg mL-1 for CD-14, 5 fg mL-1 for IGF-1,
70 fg mL-1 for PEDF and 8 fg mL-1 for VEGF-D for single detection. Good
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reproducibility is illustrated by the small error bars obtained for calibration curves
(Figure 4.5 A-D & I-K), which were linear over 2 orders of magnitude
concentration.

Figure 4.5 A-H: Calibration plots for individual protein in 5x diluted calf serum at 0.2 V vs Ag/AgCl for (A) CD-14, (B) IGFBP-3, (C) ERG, (D) GOLM; and also
showing amperometric responses for (E) CD-14, (F) IGFBP-3, (G) ERG, (H)
GOLM.
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Figure 4.5 I-N: Calibration plots for individual protein in 5x diluted calf serum at 0.2 V vs Ag/AgCl for (I) PEDF, (J) VEGF-D, (K) IGF-1, and also showing
amperometric responses for (L) PEDF, (M) VEGF-D, (N) IGF-1.

4.4.3 16-Electrode System
4.4.3.1 Single Biomarker Detection
The optimal conditions for Ab1 and Ab2 obtained on the 8-electrode
system above (Figure 4.4), were utilized for single biomarker detection on the 16electrode system. The Ab1-modified array was first placed into the detection
chamber, connected to the microfluidic set-up and washed for 2 min with PBST20 to block for NSB. The direction of flow was then switched to direct flow from
the capture chamber to waste. Magnetic bead conjugate was then injected into
the loop and flow resumed to introduce the conjugate into channel 1. The magnet
bar was placed on the port of the capture chamber to trap the beads in the
channel as the protein analyte was introduced. Incubation was then allowed for
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10 min for the protein to be captured by the bead conjugate. Direction of flow,
was then switched to introduce the second magnetic bead conjugate and protein
analyte in channel 2. 10 min incubation was allowed on channel 2 for the analyte
to be captured by bead conjugate.
After 10 min incubation on capture chamber, direction of flow was
changed and the protein-bead conjugate was then introduced into the detection
chamber, followed by a 10 min incubation to allow the protein-bead conjugate to
be captured by the Ab1 on the array. The array was then washed for 3 min with
PBS-T20 to remove any unbound conjugate followed by washing for additional 3
min with 1 mM HQ solution. Amperometric signal was then generated by injecting
a mixture of 1 mM HQ and 0.1 mM H2O2. The same protocol was employed on
channel 2 for the second protein analyte. Total assay time from incubation with
protein analyte to detection is ~45 ± 5 min for the two protein analytes (~25 min
for each protein analyte).
Employing the above protocol, calibration plots were developed for the all
the 8 proteins. Peak current increased linearly with increasing concentration of
the protein analyte from 8 pg mL-1 to 68 ng mL-1 (Figure 4.6 A-H & I-P). Detection
limits measured as 3 times the standard deviation above the control were 80 pg
mL-1 for IGFBP-3, 10 pg mL-1 for ERG, 8 pg mL-1 for GOLM-1, 140 pg mL-1 for
PSA, 250 pg mL-1 for CD-14, 10 pg mL-1 for IGF-1, 90 pg mL-1 for PEDF and 20
pg mL-1 for VEGF-D for single detection (Table 1). These detection limits and
dynamic range were higher than the ones observed on the 8-electrode system.
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This is due to the reduction of the assay time from 45 min for individual protein
on the 8 electrode system to ~25 min for each protein analyte on the 16electrode system. This dynamic range is suitable for the protein panel since most
of the proteins have concentrations in the ng mL -1 to ug mL-1 range in serum
samples. The sensitivity of the immunoarray from the slope of the calibration
curve ranged from 5.73 to 12.8 μA mL [ng protein] -1 cm-2 for all the protein
standards in undiluted calf serum.

Figure 4.6 A-H: Amperometric responses for individual protein in 5x diluted calf
serum at -0.2 V vs Ag/AgCl for (A) PSA, (B) GOLM, (C) VEGF-D, (D) IGF-1; and
also showing calibration plots for (E) PSA, (F) GOLM, (G) VEGF-D, (H) IGF-1.
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Figure 4.6 I-P: Amperometric responses for individual protein in 5x diluted calf
serum at -0.2 V vs Ag/AgCl for (I) IGFBP-3, (J) PEDF, (K) ERG, (L) CD-14; and
also showing calibration plots for (M) IGFBP-3, (N) PEDF, (O) ERG, (P) CD-14.

4.4.3.2 Multiplex Biomarker Detection
For multiplexed detection of the protein panel on the 16 electrode system,
the protein panel was grouped into two depending on their reported
concentration range in serum samples (Figure 4.3). Low concentration protein
panel (PSA, ERG, IGF-1 and VEGF-D) were assayed on channel 1 while the
high concentration protein panel (GOLM-1, PEDF, IGFBP-3 and CD-14) were
assayed on channel 2. Furthermore, IGF-1 was separated from IGFBP-3 to
minimize cross-reactivity. Primary antibodies for each protein were attached to
two of the 8-electrodes on the array. HRP-labeled magnetic beads with
antibodies for PSA, ERG, IGF-1 and VEGF-D were combined, re-dispersed in
PBS, and injected as a mixture into the capture chamber channel 1, followed by
injection of a mixture of the four protein standards. Similarly, HRP-labeled
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magnetic beads with antibodies GOLM-1, PEDF, IGFBP-3 and CD-14 were
combined, re-dispersed in PBS, and injected as a mixture to capture chamber
channel 2, followed by injection of a mixture of these four protein standards. All
steps including incubation, washing, transport to detection chamber and
detection were done as described above for single biomarkers on the 16electrode system.
Calibration data for the target proteins are shown in Figure 4.7. Good
reproducibility is illustrated by the small error bars obtained for calibration curves
(Figure 4.7), which were linear over 2 orders of magnitude concentration. The
sensitivity of the immunoarray from the slope of the calibration curve ranged from
4.17 to 9.98 μA mL [ng protein]-1 cm-2 for all the protein standards in undiluted
calf serum (Table 1). The decrease in sensitivity is due to cross-reactivity
between the protein analytes.
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Figure 4.7: Calibration plots for a mixture of protein analytes in 5x diluted calf
serum at -0.2 V vs Ag/AgCl for (A) IGFBP-3, (B) ERG, (C) GOLM, (D) PSA, (E)
CD-14, (F) IGF-1, (G) PEDF and (H) VEGF-D.

Table 4.1: Detection limits and sensitivities of the 8-protein panel on the 16electrode system.
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4.5 Discussion
Results described above demonstrate that the novel 16-electrode system
can accurately detect a panel of 8 proteins simultaneously in diluted calf serum.
Inclusion of automated syringe pump and 2-channel capture with ports to hold
the magnet bar, enhances a degree of automation to the new set up. Only
loading of reagents and samples is required by the operator, unlike the 8electrode system which still required the operator to hold the magnet bar
manually on the capture chamber. As in the 8-electrode system, the magnetic
beads can be easily manipulated by external magnets enabling wash steps to be
done with much ease in the microfluidic device. The beads also provide a high
surface to enable efficient capture of secondary and enzyme label for signal
amplification.28 A clear advantage is the speed, sample size, and multiplicity of
the immunoassays over ELISA, which requires 100 µL serum for each single
protein assay.28,29
Sensitivities of immunoarray assays obtained from the slope of the
calibration curves ranged from 5.73 to 12.8 μA mL [ng protein]-1 cm-2 for single
detection and 4.17 to 9.98 μA mL [ng protein] -1 cm-2 for multiplexed detection of
the proteins on the 16-electrode system. The decrease in sensitivity was due to
minimal cross-reactivity observed across the protein panel. However, a wide
dynamic range (8 pg mL-1 to 68 ng mL-1) was obtained that would enable
detection of the proteins in serum samples. The overall accuracy of the assay in
complex mixtures will be determined by correlation between immunoarray results
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with those obtained by standard ELISAs for human patient serum levels. The
hypothesis that these biomarker proteins could distinguish between aggressive
and indolent forms of prostate cancer would also be investigated by assaying
serum samples from prostate cancer patients in Ireland and US.
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CHAPTER FIVE
Bioconjugation of Antibodies and Enzyme Labels onto Magnetic
Beads

5.1 Abstract
Immunoassays employ antibodies and labels to capture and detect target
macromolecular analytes, often from complex sample matrices such as serum,
plasma, or saliva. The high affinity and specificity of antibody-antigen interactions
makes immunoassays critically important analytical techniques for clinical
diagnostics as well as other research applications in the areas of pharmaceutical
and environmental analysis. Integration of magnetic beads (MBs) into
immunoassays and other bioanalytical methodologies is a valuable approach to
allow efficient target capture, enrichment and convenient separation. In addition,
large signal amplification can be achieved by pre-concentration of the target and
by attaching many thousands of enzyme labels to the MBs. These features have
enabled MB-based biosensors to achieve ultra-low detection limits needed for
advanced clinical diagnostics that are challenging or impossible using traditional
immunoassays. MBs are employed either as mobile substrates for target analyte
capture, as detection labels (or label carriers), or simultaneously as substrates
and labels. For optimal assay performance it is crucial to apply an easy, efficient
and robust bead-probe conjugation protocol, and to thoroughly characterize the
bioconjugated products. Herein, we describe methods used in our laboratory to
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functionalize MBs with antibodies and enzyme labels for ultrasensitive detection
of protein analytes. We also present detailed strategies for characterizing the
magnetic bead bioconjugates.

5.2 Introduction
Novel technologies are greatly needed to enhance laboratory productivity
and provide rapid, accurate and sensitive methods for detection of various
macromolecules such as protein biomarkers, DNA and small molecules for early
disease diagnosis.1 Recent advances in nanotechnology, in particular in the
areas of nanomaterials, have advanced immunoassays towards the development
of new generation of point-of-care (POC) devices that could significantly enhance
test speed and sensitivity.2 Integration of nanomaterials, such as magnetic beads
(MBs), quantum dots and carbon nanotubes, into immunoassays as detection
labels, or as substrates onto which target is captured have important
advantages.3,

4

Nanomaterials of various sizes, shapes and compositions have

been developed and extensively utilized, providing exciting possibilities for rapid
and highly sensitive detection systems.5
Among these nanomaterials, MBs have attracted much attention in
immunoassays owing to their unique properties. The most useful MBs for
bioconjugation feature a magnetic core surrounded by a non-magnetic polymer
coating for attachment of biomolecules (Figure 5.1). Iron oxides such as
magnetite (Fe3O4) or maghemite (γFe2O3) are preferentially used as core
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material due to their stability. The outer polymer coating serves to add surface
functional coating to the beads and protects the metal oxide from external media.
6, 7

To prevent agglomeration, superparamagnetic nanoparticles are usually

dispersed or embedded into a matrix such as polystyrene, silica, dextran and
albumin.

The

most

commonly

employed

MBs

in

immunoassays

are

superparamagnetic or non-remnant. These beads have nominally zero
magnetization in the absence of a magnetic field but become magnetic in an
applied magnetic field. When fabricated with a dense superparamagnetic
nanoparticle center embedded in polymer housing, the resulting MBs behave as
non-magnetic particles in the absence of magnetic fields, although a bit of
aggregation may result from small non-ideal magnetic properties. A great
advantage of superparamagnetic beads as opposed to non-magnetic particles is
their ease of manipulation with simple, inexpensive permanent magnets or
electromagnets. Very efficient isolation of target analytes from biomedical
samples can be achieved by both manual and automated systems. 2, 4, 6, 8
Magnetic beads of various sizes, densities, magnetic susceptibilities,
material composition and a wide variety of surface chemistries are commercially
available from companies such as Invitrogen, Solulink, Micromod, Bangs Labs,
and Merck with diameter ranging from 10 nm to 50 μm. The user can choose the
desired surface chemistry to link the molecules of interest. MBs conjugated with
antibodies provide large surface area per unit volume to enable efficient capture
of target analytes. As a result, the sensitivity of the assays is increased due to
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the high efficiency of interaction between the sample and reagents that can
provide large pre-concentration factors. Moreover, MBs can be easily dispersed
into the sample matrix with gentle shaking hence faster binding kinetics can be
achieved.3, 6 In addition to the ease of manipulation, shorter assay time and high
sensitivity, MBs are compatible with diverse detection and signal processing
approaches,

electrochemiluminiscence,9,10

including

surface

Plasmon

resonance11, 12 and electrochemical detection.2, 4, 8
Our laboratory has exploited MBs conjugated with massive copies of
antibodies and enzyme labels in electrochemical immunosensors for a series of
prostate and oral cancer biomarkers.13-17 MBs conjugated with 10s of thousands
of detection antibodies (Ab2) and up to a half million horseradish peroxidase
(HRPs)

labels

have

been

used

to

enhance

the

sensitivity

of

the

immunoassays.13-15, 17, 18 Ab2 and HRP attachment onto MBs, and purification of
the bead bioconjugates (MB-Ab2-HRP) is facilitated by magnetic separations.
When integrated with microfluidic systems, position of the resulting bioconjugate
beads can be magnetically controlled to facilitate faster assay times. Heavily
labeled detection particles have led to detection limits in low fg/mL range,
enhancing sensitivity 100-1000 times as opposed to conventional immunoassays
using singly-labeled Ab2’s.8,

16, 19

High local concentrations of antibodies on the

beads greatly favor the binding of protein analytes20 while the multiple enzyme
labels amplify signals.3,

21

However, in order to obtain the high sensitivity and
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reproducibility of immunoassays, an easy, efficient and robust bead-probe
conjugation protocol needs to be employed.

5.3 Bioconjugation of Magnetic beads
For optimal bioanalytical performance, it is crucial to employ a suitable
and reproducible method for bioconjugation of MBs with specific recognition and
signal triggering elements. Choice of conjugation strategy is dictated by a
combination of factors including MBs size, nature of the MB surface coating,
available functional groups, or the type of biological molecule and its chemical
composition.5, 21 Commercial MBs are available with a wide variety of functional
groups such as amine, carboxyl, epoxy, tosyl, hydroxyl, N-hydroxysuccinimide as
well as biological molecules such as biotin, streptavidin, protein A, protein G and
antibodies (Figure 5.1).6, 7
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Figure 5.1: Variety of commercially available functionalized MBs with coatings of
either organic functional group to attach biomolecules or biomolecules that can
bind specific moieties.

Biomolecules can be conjugated to the surface coatings of MBs either
directly, or using cross-linkers or other reagents (see Figure 5.1). Bioconjugation
approaches usually include non-covalent interaction such as physical adsorption,
specific affinity interaction, entrapment of molecules around the magnetic beads,
and covalent interaction of biomolecules with the functional groups on MBs
surface.5,

21

Functional groups can be activated for coupling using EDC-NHSS

chemistry for carboxylates or glutaraldehyde for amines to attach appropriate
functional groups of biomolecules. Particles pre-coated with streptavidin can
capture biotin-labeled biomolecules. Surface tosyl-, NHS-activated and epoxide
groups on MBs can be used to attach biomolecules directly without crosslinking
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agents. Protein A coated particles can selectively bind to Fc regions of antibodies
for oriented immobilization.6
Herein, we provide detailed protocols used in our laboratory to
functionalize MBs with both antibodies as recognition elements and HRP as
signal triggering element, also known as dual-labeling of MBs, for ultrasensitive
detection of protein cancer biomarkers. We provide protocols used for
conjugation of streptavidin-coated MBs as well as tosyl-activated MBs and
highlight the strategies employed for optimization and characterization of the
bioconjugates.

5.4 Preparation of dual-labeled magnetic beads
5.4.1. Tosyl-activated Magnetic Beads
Tosyl-activated magnetic beads provide reactive sulphonyl esters that
covalently link antibodies or other ligands that contain primary amino or
sulphydryl groups to the magnetic particle surface (Figure 5.2). Immobilization of
antibodies on these MBs occurs via the Fc region thus ensuring optimal
orientation of the antibody, resulting in higher capture yield of the target analyte.
The physical adsorption of the antibodies to the magnetic particle surface is
rapid, however the formation of covalent bonds requires more time. Therefore,
preparation of these conjugates should take place at 37 oC for 24 hours.
Additional incubation with blocking buffers containing 0.01-0.5% BSA solution aid
in minimizing non-specific binding (NSB) from occurring and increase the
functionality of the coupled antibodies and enzyme labels. Buffers used for
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preparation of antibody conjugates should be removed of any reactive groups
including amines, thiols, and hydroxyls as well as any sugars and stabilizers that
may interfere with binding. To facilitate the coupling efficiency buffers with high
ionic strength should be used as they stimulate hydrophobic interactions. In
addition tosyl groups are more reactive at higher pH, therefore sodium borate
buffer (pH 9.5) should be used.

Figure 5.2: (A) The covalent attachment of antibodies to the tosyl functionalized
magnetic particles. The tosyl groups act as leaving groups for surface amine
groups present on antibodies to attach. (B) The complete conjugation protocol for
both the attachment of antibodies as well as HRP enzyme labels.

1. Vortex the medium slurry of the tosyl-activated MBs (Dynabeads®
MyOne™ Tosylactivated product no. 65501) to homogeneity before
dispensing.
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2. Transfer 20 μL (100 mg/mL) of tosyl-activated MBs to a 1.5 mL
microcentrifuge tube and suspend in 600 μL of 0.1 M sodium borate buffer
(pH 9.5).
3. Place the microcentrifuge tube on a magnet (Invitrogen Dynal magnet) for
2 mins and discard the supernatant. Resuspend the tosyl-acivated
magnetic beads in 600 μL of 0.1 M sodium borate buffer (pH 9.5).
4. Repeat step 3 once more to ensure the excess sulphonyl esters are
removed from tosyl-activated MBs. Once supernatant is removed,
resuspend MBs in 290 μL of 0.1 M sodium borate buffer (pH 9.5), 207 μL
of 3 M ammonium sulfate (pH 9.5) and 80 μL (0.02-1 mg/mL) of desired
concentration of antibody (Ab2), all into the microcentrifuge tube.
5. Incubate the microcentrifuge tube with its contents (MB-Ab2) at 37oC for
24 hours with slow tilt rotatation (Invitrogen Dynabeads MX mixer).
6. Following incubation place the microcentrifuge tube on a magnet
(Invitrogen Dynal magnet) for 2 mins and discard the supernatant
removing

any

excess

unbound

antibody

(Ab2).

Resuspend

the

bioconjugates with 600 μL of 20 mM phosphate buffer containing
detergent Tween-20 (pH 7.4).
7. Place the microcentrifuge again on the magnet (Invitrogen Dynal magnet)
for 2 mins and discard the supernatant. Resuspend the MB-Ab2 with 625
μL of 3 mg HRP in 0.5% BSA in phosphate buffer (pH 7.4).
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8. Incubate the bioconjugate for 18 hours at 37 oC with slow rotation to
attach HRP to MB-Ab2 to form HRP-MB-Ab2.
9. Place the BSA blocked HRP-MB-Ab2 bioconjugates on a magnet
(Invitrogen Dynal magnet) for 2 mins and discard the supernatant
removing any excess unbound HRP. Resuspend the HRP-MB-Ab2
bioconjugate in 625 μL 0.1% BSA in phosphate buffer (pH 7.4).
10. Repeat wash (step 9) 3 times. Once sufficiently washed re-suspend the
HRP-MB-Ab2 bioconjugates in 625 μL 0.1% BSA in phosphate buffer (pH
7.4). Place the conjugates at 4oC until further use. These HRP-MB-Ab2
can be used for 2-3 weeks without noticeable degradation in
performance.13

5.4.2. Streptavidin-coated Magnetic Beads
Streptavidin magnetic beads contain a monolayer of streptavidin
covalently coupled to the surface of the beads. This streptavidin monolayer has a
high affinity for biotinylated biomolecules (Figure 5.3). The binding of streptavidin
to biotin is one of the strongest known non-covalent biological interactions with
femtomolar affinity constants.22 Once the streptavidin tetramer is bound to the
surface of the magnetic beads there are two or three biotin binding sites available
for each streptavidin molecule on the surface of the bead after immobilization.
Streptavidin’s high affinity for biotin enables biotinylated biomolecules to be
captured within 25 mins at 37 oC, this greatly reduces conjugate preparation
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times. We recommend a ratio of 1:2:4 for MBs:Ab2:HRP when preparing the
streptavidin MB conjugates.

Figure 5.3: The non-covalent attachment of biotin-antibodies and biotinHorseradish Peroxidase labels to the surface of streptavidin-coated MBs.
1. Vortex the medium slurry of the streptavidin MBs (Dynabeads® MyOne™
streptavidin T1 product no. 65601) to homogeneity before dispensing.
2. Transfer 20 μL (10 mg/mL) of streptavidin MBs to a 1.5 mL
microcentrifuge tube and suspend in 200 μL of 0.1% BSA in phosphate
buffer (pH 7.4).
3. Place the microcentrifuge tube on a magnet (Invitrogen Dynal magnet) for
2 mins and discard the supernatant. Re-suspend the streptavidin magnetic
beads in 200 μL of 0.1% BSA in phosphate buffer (pH 7.4).
4. Repeat (step 3) 2 more times to ensure the excess storage solution is
removed from streptavidin MBs. Once supernatant is discarded from the
third wash, resuspend MBs in 80 μL of 0.1% BSA in phosphate buffer (pH
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7.4), 40 μL (0.02-1 mg/mL) of desired concentration of antibody (Ab 2), and
80 μL of biotinylated-HRP (2.5 mg/mL), all into the microcentrifuge tube.
5. Incubate the microcentrifuge tube with its contents (streptavidin-MB-biotinAb2-biotin-HRP) at 37oC for 25 mins with slow tilt rotation (Invitrogen
Dynabeads MX mixer).
6. Place HRP-MB-Ab2 bioconjugates on a magnet (Invitrogen Dynal magnet)
for 2 mins and discard the supernatant. Resuspend the HRP-MB-Ab2
bioconjugate in 200 μL 0.1% BSA in phosphate buffer (pH 7.4).
7. Repeat (step 6) 3 times to remove any excess unbound Ab 2 and HRPs.
Once sufficiently washed resuspend the HRP-MB-Ab2 bioconjugates in
200 μL 0.1% BSA in phosphate buffer (pH 7.4). Place the conjugates at
4oC until further use. The HRP-MB-Ab2 can be used for 2 weeks without
noticeable degradation in performance.15

5.5 Characterization of magnetic bead bioconjugates
To establish control of MB bioconjugate preparation, the conjugates need
to be characterized in order to determine the amount of both the antibodies as
well as signal generating enzyme labels. For measuring HRP activity and
amount, we recommend the the use of 2,2′-Azino-bis(3-ethylbenzothiazoline-6sulfonic acid) (ABTS) enzymatic assay. The Bicinchoninic acid (BCA) protein
assay can be used to determine the total number of active HRP and Ab 2 bound
to MBs respectively. Since BSA is an interfering agent in BCA assay, the last
washing step in the bead preparation protocol should be performed using PBS
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buffer and not 0.1% BSA, prior to characterization to avoid measuring residual
bound BSA.

5.5.1 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)
Enzymatic Assay
The ABTS or (2,2’-azino-bis(3-ethylbenzthiasoline-6-sulfonic acid) assay
is a colorimetric assay based on the ABTS cation radical formation. 23,

24

The

radical formation is catalyzed by the reduction of horseradish peroxidase in the
presence of hydrogen peroxide (Figure 5.4). The ABTS cation radical exhibits a
change of color from slightly yellow to an intensely turquoise colored solution with
an absorbance of 405 nm. Employing this assay, we are able to determine the
number of active signal generating HRP labels present on the MB bioconjugates.

Figure 5.4: Formation of the 2,2’-azino-bis(3-ethylbenzthiasoline-6-sulfonic acid
(ABTS) radical catalyzed by horseradish peroxidase in the presence of hydrogen
peroxide.

1. Prepare tosyl-activated and streptavidin-coated bead conjugate (HRP-MB-

Ab2) as outline above and also a set of the tosyl-activated bead conjugate
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without HRP (MB-Ab2). The last washing step should be performed using
20 mM phosphate buffer.
2. Prepare 100 mM potassium phosphate buffer in deionized water at pH 5.0

at room temperature.
3. Prepare 9.1 mM 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)

substrate solution (ABTS) (Sigma-Aldrich, product no. A9941) in
potassium phosphate buffer ph 5.0 (step 2).
4. Prepare 0.3% (w/w) hydrogen peroxide solution in deionized water.
5. Set spectrophotometer to kinetic mode sampling at 405 nm calculating

initial rate every second from 5-120 sec.
6. Blank the spectrophotometer with potassium phosphate buffer (step 2).
7. Immediately mix the reagents as indicated below by inversion and record

the ΔAbsorbance for approximately 2 mins.

Table 5.1 Reagents/Sample Volume for ABTS Assay
Reagents/ Sample

Test

Blank

9.1 mM ABTS solution

2.9 mL

2.9 mL

PBS buffer or MBs in PBS buffer

-

50 µL

MB-Ab2 (Tosyl-activated beads)

50 µL

-

HRP-MB-Ab2 (Tosyl and streptavidin 50 µL

-

beads)
0.3% H2O2

100 µL

100 µL
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8. The number of HRPs per MB is determined by performing the calculations

below, where 3.05 is the total volume in mL of the assay, d.f is dilution
factor (10 - 50x), 36.8 is the mM extinction coefficient of oxidized ABTS at
405 nm and 0.05 is the volume in mL of enzyme used.

Units/ mL enzyme is then converted to the moles of HRP using pyragallol
units in HRP, Avagadros number, and molecular weight. The number of HRP per
MB is obtained by diving the moles of HRP by beads per mg of the MBs (1012
beads/mg for tosyl-activated beads and 108 beads/mg of streptavidin-coated
beads).

5.5.2 Bicinchoninic acid (BCA) Protein Assay
Bicinchoninic acid (BCA) assay or Smith assay is a copper-based
colorimetric assay for total protein quantification. BCA rely on the formation of a
Cu2+-protein complex in a basic environment, followed by reduction of the Cu 2+ to
Cu+.25 The amount of Cu2+ that is reduced is proportional to the amount of protein
present in solution. Basically, two molecules of bicinchoninic acid chelate to each
Cu+ ion causing a change of color of the sample solution from green to purple
that exhibits a strong absorbance at 562 nm (Figure 5.5). The bicinchoninic Cu+
complex is influenced by both the number of peptide bonds, as well as the
presence of amino acids cysteine, cystine, tyrosine, and tryptophan side
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chains.26 Elevated temperatures increase exposure of amino acids and minimize
the differences caused by unequal amino acid composition in different protein
samples. Therefore, to increase assay sensitivity the assay should be performed
at an elevated temperature of 60oC.

Figure 5.5: The formation of the Bicinchoninic acid (BCA)-copper complex for
the BCA total protein assay. This assay proceeds in two steps; the first being the
reduction of Cu2+ by antibodies in a basic environment and the second step
involves the reduced Cu+ chelating with two molecules of bicinchoninic acid.

1. Prepare standard concentrations of detection antibody (Ab2) with
concentrations ranging from 1.25-20 μg/mL.
2. Formulate dilutions of MB-Ab2 for tosyl-activated beads and HRP-MB-Ab2
for tosyl-activated and streptavidin-coated beads (5-20 dilution factors).
3. Mix a stock solution of the BCA reagents, Pierce™ BCA Protein Assay Kit
product number 23225 (25 parts of reagent MA + 24 parts of reagent MB
+ 1 part reagent MC).
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4. Add 500 μL of the samples in step 1 & 2 and PBS buffer or MBs as blank
to 500 μL of the stock solution of BCA in step 3.
5. Incubate the samples in step 4 at 60 ˚C for 1 hour for the complex
formation.
6. Cool all the samples to room temperature.
7. Measure the absorbance of all the samples at 562 nm within 10 minutes.

Figure 5.6: The workflow for the Bicinchoninic acid (BCA) total protein assay
including the formation of the working reagent, and the development of a
standard curve from a range of antibody concentrations.

8. By subtracting absorbance of MB from that of MB-Ab2 and HRP-MB-Ab2,
the unknown concentration of antibodies on the MB can be found from the
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calibration plot of antibody standards obtained with the BCA kit (Figure 7).
The number of antibodies on MP surface is obtained by dividing the
number of antibodies in the dispersion by the number of particles in the
dispersion ((1012 beads/mg for tosyl-activated beads and 108 beads/mg of
streptavidin-coated beads).

Figure 5.7: Calculating the total antibody concentration from subtracting the
absorbance of the magnetic beads from that of the magnetic beads containing
the antibody.

5.6 Integration of magnetic beads into Immunoassay
Sensitive and selective immunoassays rely on the ability to fish out a
protein analyte of interest from an ocean containing thousands of other proteins.
MBs conjugated with highly selective antibodies as well as other protein capture
agents provide a simple and effective way to achieve this goal. Typically, the dual
labeled magnetic beads are added to a fluid sample, the sample is then mixed in
order for proteins to be selectively captured by antibodies that are present on the
MBs. Once protein analytes are captured any interfering biomolecules present on
the bead surface are removed through washing protocols involving magnetic
separation that is either manual13-15 or automated.17,

18

Labels present on the
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bead surface such as HRPs are then detected to measure the selected protein
analyte of interest.
A major factor influencing the selectivity and sensitivity of immunoassays
is non-specific binding (NSB). NSB occurs when MB bioconjugates binds to nonantigen sites on the sensor during immunoassay fabrication. Generally, MB
bioconjugates generate a signal even if it is bound to sites other than the analyte
protein-capture antibody complex. Therefore, signals arising from NSB cannot be
differentiated from those originating from antigen-antibody binding, and are not
proportional to the analyte concentrations. As a result, NSB raises the detection
limit and greatly decreases the sensitivity of the assay. Solving this problem
involves creating a sensor surface that inhibits any other binding other than that
of the protein antigen with its antibodies. Bovine serum albumin (BSA) or casein
with small quantity of detergent such as T-20 in wash buffers are commonly
employed to minimize NSB in assays. However, there is no universal blocking
agent for NSB in any protein detection system, therefore a thorough
characterization of the amplifying formulation is needed to avoid NSB in any
amplification strategy. Employing 2% BSA in PBS-T20 on the sensors and 0.1%
BSA in PBS-T20 on MB bioconjugates have greatly inhibited NSB in our assays
enabling ultralow detection limits to be achieved.14, 15, 17, 18
In order to achieve the ultralow detection limits in immunoassays, the
concentration of antibodies should be optimized on the MB bioconjugates
(HRPMB- Ab2). Usually, MB bioconjugates are prepared with a wide range of
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concentrations for detection antibody (Ab2) and tested for their immunoassay
performance. Keeping the concentration of capture antibody (Ab 1) on the
detection platform constant, a blank and a standard sample are tested with
different MB-bioconjugates with varying concentrations of Ab2. The MB
bioconjugates with the highest difference between the blank and the sample is
then chosen for immunoassay applications.18 The Ab1 on the detection platform is
optimized as well by varying the concentration of Ab 1 and keeping the
concentration of Ab2 on the MB bioconjugates constant. The key factors that play
a role in the MB-bioconjugate with optimal concentration of antibodies are
orientation and binding capacity.
Integrating these MB-based immunoassays in microfluidic systems adds
to many key advantages in development of a high performance assay as these
systems can reproducibly deliver these MB bioconjugates to desired locations in
a simple and rapid manner. However, MBs may adsorb to microfluidic device
surfaces due to these micrometer-dimensioned channels and micron tube
diameters, leading to clogged channels, and an increase in flow resistance. 27 In
order to minimize the risk of clogging and decreased assay performance it is
recommended that microfluidic tubing be changed every few months and device
systems be thoroughly washed with detergents after each use. We also
recommend the use of 4–5 times diluted MB bioconjugate (HRP-MB-Ab2) in
immunoassays.
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The development of MB bioconjugates for protein capture, manipulation,
transport, and labeling has enabled the detection of a library of known cancer
biomarker proteins. These proteins are detected at clinically relevant serum
levels and have clearly demonstrated their utility in both manual and automated
capture systems. There is no doubt that these magnetic bead based
technologies are/ will be important tools for future protein detection systems.
Interfacing these relatively simple protocols with microfluidic or other automated
sample handling technologies will further propel MB protein detection systems
into the clinical setting.
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